Dissection of receptor functions through the generation of a tcu-PA cleavage resistant u-PAR: a u-PA independent active u-PAR by Nieves, Evelyn
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
© 2012 Evelyn C. Nieves 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
DISSECTION OF RECEPTOR FUNCTIONS THROUGH THE GENERATION OF A 
TCU-PA CLEAVAGE RESISTANT U-PAR: A U-PA INDEPENDENT ACTIVE U-
PAR 
 
 
 
BY 
 
EVELYN C. NIEVES 
 
 
 
 
 
 
 
 
 
DISSERTATION 
 
Submitted in partial fulfillment of the requirements  
for the degree of Doctor of Philosophy in Biochemistry  
in the Graduate College of the  
University of Illinois at Urbana-Champaign, 2012 
 
 
 
 
 
 
Urbana, Illinois 
    
Doctoral Committee:  
    Professor Bradford S. Schwartz, Chair  
    Professor James H. Morrissey 
    Professor Emeritus George Ordal  
    Assistant Professor Rutilio A. Fratti 
ii 
 
  Abstract 
 
 The regulation of protease activity is essential for physiological events, such as 
angiogenesis, inflammation, wound healing, and tumor invasion.  Urokinase plasminogen 
activator receptor (u-PAR) has been widely studied in both systemic and cellular 
processes. Systemic roles for u-PAR include angiogenesis, inflammation and cancer 
while cellular roles include cell proliferation, survival, adhesion, migration, and 
localizing activation of plasminogen (Pg) (Blasi, Behrendt et al. 1990; Ellis, Behrendt et 
al. 1991; Nguyen, Hussaini et al. 1998; Chapman, Wei et al. 1999).   u-PAR exerts its 
effects through both proteolytic and non-proteolytic mechanisms that are inter-related. 
Both functions are directly affected by the activation of u-PAR through the binding of its 
cognate ligand, urokinase plasminogen activator (u-PA).   
u-PAR is a glycosidylphosphatidylinsotol (GPI)-anchored receptor that has the ability 
to activate Pg through localization of u-PA to the cell surface. In malignant cells, the 
increased glycosylation of u-PAR confers resistance to cleavage by two-chain urokinase 
plasminogen activator (tcu-PA) (Montuori, Rossi et al. 1999).  Interestingly, the presence 
of highly glycosylated receptor prevents the tcu-PA from cleaving domain 1 (D1) by 
decreasing u-PA’s affinity for u-PAR.   
The central hypothesis of the work described here involves the sensitive balance that 
is created by the binding of u-PA to u-PAR for both the activation and functional 
regulation of these proteins. u-PAR has the ability to localize u-PA to the cell surface to 
initiate Pg activation.  tcu-PA also has the ability to cleave D1 of u-PAR from the rest of 
the protein, which prevents localization of u-PA on the cell-surface.   
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To explore and characterize this relationship, we engineered a mutant u-PAR that 
prevents cleavage of D1, and studied the effects on the activation of Pg, u-PAR dependent 
cellular migration and proliferation.  Mutation of residues Arg 83 and Arg 89 in u-PAR 
leads to conformational changes that resemble the active conformation of u-PAR 
previously observed in crystal structures (Llinas, Le Du et al. 2005; Barinka, Parry et al. 
2006; Huai, Mazar et al. 2006).  Although our studies indicate that the initiation of the Pg 
activation cascade of our u-PAR mutants is essentially indistinguishable from wild type 
wt u-PAR, we also show an acceleration of the rate at which u-PA-PAI-1 complexes are 
cleared by α2-macroglobulin receptor/ low-density lipoprotein receptor-related protein 
(LRP) through u-PAR binding. In addition, we observe an increase in cell proliferation, 
cell migration and changes in cell morphology that correlates with an increase in ERK 
signaling. 
The u-PAR:LRP interaction we identified was remarkably novel, although one 
publication related u-PAR to LRP via binding the u-PA-PAI-1 complex, with u-PAR 
with minimal interaction via domain 3 of u-PAR (Czekay, Kuemmel et al. 2001).  The u-
PAR:LRP interaction we observed was supported by an increase in u-PAR detection 
when the mutant receptor was co-immunoprecipitated with an antibody against LRP. A 
similar increase was not observed with wt u-PAR.  We also observed a direct impact on 
cell migration, adhesion and proliferation that are known to be u-PA dependent. 
The ability of u-PAR to aid in cellular motility in response to local environment is 
intriguing, in light of the fact that there is a correlation between plasma levels and the 
amount of intact su-PAR found in cancer patients (Bifulco, Longanesi-Cattani et al. 
2011). The ability of highly glycosylated u-PAR molecules to increase proliferative 
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events is also of interest. Over-glycosylation of u-PAR leads to resistance to cleavage by 
its cognate ligand, tcu-PA (Sier, Nicoletti et al. 2004). In addition, this effect is 
pronounced in highly metastatic anaplastic thyroid carcinoma (Montuori, Rossi et al. 
1999).  Studying the mechanisms used by u-PAR in vitro and in vivo provides great 
insight into which u-PAR activities are important in cancer. The expression of u-PAR in 
both neoplastic cells and tumor-associated cells from ovary, colon, lung, breast, 
endometrium, macrophages, endothelial cells, and ﬁbroblasts indicates that u -PAR may 
be a useful therapeutic target since researchers have been able to correlate prognosis and 
u-PAR expression levels (Mazar 2001; Wang, Mao et al. 2001; Ge and Elghetany 2003; 
Sidenius and Blasi 2003; Mazzieri and Blasi 2005). Furthermore, u-PAR may be useful 
as a prognostic marker for cancer and to detect metastasis at an early stage. Generation of 
a non-cleavable u-PAR provides information regarding what relative roles are played by 
the intact and cleaved forms of the receptor.   
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CHAPTER 1. INTRODUCTION 
1.1.Regulation of u-PAR mRNA 
Urokinase plasminogen activator receptor (u-PAR), is a species-specific, cognate 
cell-surface receptor for urokinase plasminogen activator (u-PA).  The human u-PAR 
gene (PLAUR) has been localized to chromosome 19q13.2.  It spans 23 kb of genomic 
DNA and contains seven exons and six introns (Borglum, Byskov et al. 1992).  The u-
PAR gene shares approximately 76 % sequence homology between mouse, bovine and 
rat u-PAR (Reuning, Little et al. 1993).  Expression levels for u-PAR range from 50,000 
to 200,000 receptors per cell in normal cells, with a 4-5 fold increase in expression in 
cancer cells (Plow, Freaney et al. 1986). 
Regulation of u-PAR expression occurs at both the transcriptional and post-
transcriptional levels.  The u-PAR gene contains a promoter region -141 to +47 bp 
relative to the transcription initiation site (Fig. 1.1.1) (Wang 2001).  The TATA and 
CAAT boxes are missing from the upstream region of u-PAR, but it does have a GpC-
rich region containing both cis- and trans-acting factor binding sites that regulate u-PAR 
gene expression (Soravia, Grebe et al. 1995). These include a proximal AP-1, a distal AP-
1, an AP-2 and NF-κB response elements (Soravia, Grebe et al. 1995; Dang, Boyd et al. 
1999; Wang, Dang et al. 2000).  Wang et al., observed an increase in u-PAR expression 
on colon cancer cells with either tumor necrosis alpha-1 (TNF-α) or phorbol-12 myristate 
acetate (PMA) stimulation. Post-transcriptional regulation is carried out by several 
different sequence elements that promote mRNA decay or stability, including an AU-rich 
element in the 3’ untranslated region that is highly conserved among u-PAR from several 
species (Wang, Collinge et al. 1998; Nau, Guerin-Dubiard et al. 2003; Kotzsch, 
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Sieuwerts et al. 2008).  Degradation through the 3’ AU-rich element occurs as the 3’-
Poly(A) tail is shortened (Chen and Shyu 1995).  In addition, both stabilizing and 
destabilizing regulatory elements have been found in the coding region (Shetty, Kumar et 
al. 1997; Montuori, Mattiello et al. 2001; Montuori, Mattiello et al. 2003; Shetty, 
Muniyappa et al. 2004).   
 u-PAR’s cognate ligand, u-PA, has the ability to upregulate u-PAR expression.  
Promotion of u-PAR expression by u-PA occurs at the transcriptional level due to 
increased activity of the transcription factor Sp1, while post-transcriptional regulation by 
u-PA is due to changes in activity and concentration of stabilizing factors, such as the 
embryonic lethal, abnormal vision (ELAV) RNA-binding protein, Hu antigen R (HuR) 
(Tran, Maurer et al. 2003), and heterogeneous nuclear ribonucleoprotein C (hnRNPC) 
(Shetty 2005).  These stabilizing factors bind to the coding region of u-PAR mRNA, 
preventing messenger degradation (Montuori, Mattiello et al. 2001).   
 
1.2. u-PAR protein and structure 
u-PAR is a heavily and heterogeneously glycosylated glycosylphosphatidylinositol-
anchored (GPI) cell-surface protein. The apparent molecular weight of u-PAR is 50-65 
kD.  Forty percent of the molecular weight is attributed to glycosylation (Blasi, Stoppelli 
et al. 1986; Moller, Pollanen et al. 1993; Ploug 1998), and enzymatic deglycosylation of 
u-PAR results in a 35 kD protein.  Widely distributed in the body, u-PAR is expressed by 
human monocytes (Miles and Plow 1987), kidney, vascular endothelium (Miles, Levin et 
al. 1988; Barnathan, Kuo et al. 1990), fibroblasts, and sperm cells.  It is also expressed by 
several types of malignant cells (Needham, Nicholson et al. 1988; Cohen, Xi et al. 1991; 
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Ossowski, Clunie et al. 1991).  In addition, a soluble form of u-PAR (su-PAR) which 
lacks the GPI-anchor, circulates in the plasma of humans and mice (Kasperska-Zajac and 
Rogala 2005).  
The nascent u-PAR protein consists of 313 residues that encode a 21-residue 
signaling peptide, three Ly-6 domains, a 14-residue linker region, a C-terminal GPI-
anchor, and five potential glycosylation sites (Moller, Pollanen et al. 1993) (Figure 1.1.2).  
The 21-residue signaling peptide is not included in the nascent protein, since it is 
removed from the N-terminal region during post-translational modification.  In addition, 
the 30-residue peptide on the C-terminal, beginning with Gly283, is removed for 
incorporation of the GPI-anchor (Moller, Ploug et al. 1992).  The extent of glycosylation 
varies between different cell types, and may account for the differences in affinity for u-
PA.  Substitution analysis of the five potential glycosylation sites (Asn52, Asn162, Asn172, 
Asn200, and Asn233) in u-PAR determined that glycosylation at residue Asn52 is required 
both for high affinity to u-PA and for secretion of the protein (Figure 1.1.3) (Moller, 
Pollanen et al. 1993; Ploug, Rahbek-Nielsen et al. 1998).  Glycosylation of the other four 
sites aid in high affinity interactions with u-PA (Nielsen, Kellerman et al. 1988; 
Estreicher, Wohlwend et al. 1989; Ploug, Rahbek-Nielsen et al. 1998). 
 u-PAR has three highly homologous cysteine-rich domains, each consisting of 90 
residues that are linked by a total of 28 cysteines (Ploug, Kjalke et al. 1993).  These 
domains have a finger-like shape with three adjacent loops that form a planar anti-parallel 
β-sheet with four highly conserved disulfide bonds in domains 1 (D1) and 2 (D2), and 
three disulfide bonds in domain 3 (D3). Ly-6, snake venom α-neurotoxin, and 
polycythemia rubra vera 1 (PRV-1) are proteins with internal sequence homology, based 
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on cysteine residue patterns similar to u-PAR (Temerinac, Klippel et al. 2000).  u-PAR’s 
three domains form a concave shape with a maximal diameter of 52 Å and a height of 27 
Å (Barinka, Parry et al. 2006). The growth factor domain (GFD) of u-PA interacts with 
the cavity of u-PAR, making contact with all three domains. Although D1 was originally 
identified as primarily responsible for the high affinity binding of u-PAR to u-PA, 
(Ronne, Behrendt et al. 1991) it was more recently observed that both D2 and D3 also 
contribute.  Domain 2 contacts key residues of the amino terminal fragment (ATF), 
forming most of the hydrogen bonds between u-PAR and ATF. Domain 3 interacts with 
the ATF through helix α3 and forms part of the su-PAR cavity by interacting with D1, 
closing the cavity (Huai, Mazar et al. 2006).    
 Binding of u-PA to u-PAR causes conformational changes that convert the receptor 
from an inactive to an active form. This conversion allows for new interactions with other 
proteins such as vitronectin (Vtn) and some integrins (Hoyer-Hansen, Behrendt et al. 
1997; Wei, Czekay et al. 2005). Several researchers have identified regions in u-PAR that 
move upon the binding of u-PA (Huai, Mazar et al. 2006; Gardsvoll and Ploug 2007).  
Crystallization studies indicate that u-PAR undergoes major changes in inter-domain 
alignment upon ATF binding, potentially exposing new epitopes on the receptor surface 
(Barinka, Parry et al. 2006).  One such area that is altered upon ligand-binding is the 14-
residue linker region, which is a flexible unstructured loop between D1 and D2.  It does 
not directly contribute to u-PAR’s affinity for u-PA (Fig. 1.1.4).  Within this linker region 
is a key five-residue sequence, 88SRSRY92, called the “chemotactic epitope”.  This 
epitope is exposed when u-PA binds to u-PAR, as are residues essential for Vtn-binding.  
While the only crystal structure available of unliganded u-PAR contains a disulfide bond 
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that links D1 to D3, comparison of the structures of u-PAR, complexed to either a small 
inhibitory peptide or to ATF, suggests that the different ligands induce different amounts 
of conformational change in u-PAR.  The linker region is more completely resolved and 
the diameter of the central cavity is smaller when u-PAR is co-crystallized with ATF, 
rather than a small peptide.  This suggests that binding of u-PA causes changes not only 
to the cavity, but also to the linker region of the receptor (Barinka, Parry et al. 2006).  
 
1.3.Proteolytic functions of u-PAR 
1.3.1. Plasminogen activation cascade 
u-PAR is involved in the initiation of pericellular plasminogen (Pg) activation, which 
generates the broad-specificity serine protease, plasmin (Pn), from its zymogen precursor, 
Pg (Fig. 1.1.5).  Pg activation leads to the dissolution of fibrin clots and the digestion of 
extracellular matrices and basal membranes. In addition, there is strong evidence 
implicating the Pg activation cascade in cancer, i.e. colorectal cancer, breast cancer and 
prostate cancer (Duffy, Reilly et al. 1990; Pyke, Kristensen et al. 1991; Zhang, Sud et al. 
2011). Currently, the proteins in the cascade are being used as prognostic markers and 
biomarkers. Plasminogen is a 92 kD single-chain glycoprotein that is synthesized 
primarily in the liver and circulates in plasma at a concentration of 1.5-2 µM with a 
plasma half-life of approximately two days.  It has five N-terminal kringle domains, with 
the first and fourth kringle domains lending to high-affinity and low-affinity fibrin-
binding, respectively, and a C-terminal serine protease domain.  The kringle domains 
allow Pg to interact with fibrin, cell-surface receptors, and permit rapid binding of the 
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cognate inhibitor α2-antiplasmin to Pn.  Activation of Pg occurs by a single cleavage 
event of the zymogen protease domain, Arg560-Val561.   
The serine protease u-PA is a 54 kD protein that is secreted by the endothelium and 
kidneys in the zymogen single-chain form (scu-PA) (Fig. 1.1.6). The active protease is a 
two-chain form (tcu-PA) that is generated by cleavage of the peptide bond, Lys158-Ile159.  
u-PA is comprised of 411-residues that create the serine protease domain, a kringle 
domain and an epidermal growth factor (EGF) domain.  u-PA may also undergo a 
secondary cleavage at Lys136-Lys137 to produce two new fragments, the ATF and low-
molecular weight u-PA (LMW-uPA).  The ATF has no catalytic activity, since it contains 
only the EGF domain and most of the kringle domain, whereas LMW-uPA contains the 
serine protease domain. Intact u-PA binds to u-PAR with high affinity (KD 0.5 pM - 2 
nM) (Hoyer-Hansen, Ronne et al. 1992; Behrendt, Ronne et al. 1996).  The half-life of 
the u-PA:u-PAR complex is several hours (Stoppelli, Corti et al. 1985; Vassalli, Baccino 
et al. 1985), and the receptor-enzyme complex has not been observed to be taken up by 
the cell.  u-PAR amplifies the Pg activation cascade (Fig. 1.1.7) by localizing scu-PA on 
the cell-surface and augmenting the intrinsic activity of scu-PA 103-fold, thus 
accelerating the generation of Pn from the widely present precursor protein, Pg 
(Manchanda and Schwartz 1991; Ellis, Whawell et al. 1999).  Pn cleaves scu-PA to the 
active protease tcu-PA, causing feedback activation and resulting in further augmentation 
of Pn generation.  Cleavage of u-PA by Pn in the GFD of u-PA generates a 33 kDa u-PA, 
which lacks u-PAR affinity helping to regulate the Pg activation cascade (Saksela and 
Rifkin 1988). 
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Enzymatic activity of free u-PA or u-PAR-bound u-PA is inhibited by the serine 
protease in
Ginsburg, Zeheb et al. 1986
hibitor (serpin), plasminogen activator inhibitor-1 (PAI-1). PAI-1 is a 45 kD 
single chain glycoprotein consisting of 319 residues that contains a reactive peptide bond 
Arg346-Met347 ( ).  PAI-1 is found in plasma, platelets, adipose 
tissue, and in endothelial cells. It is also expressed pathologically by several types of 
neoplastic cells (e.g. hepatoma, fibrosarcoma) (Erickson, Schleef et al. 1985; Blasi, 
Vassalli et al. 1987; Juhan-Vague, Alessi et al. 1991).  PAI-1 is a rapid and efficient 
inhibitor of u-PA. PAI-1 can reversibly inhibit scu-PA, but irreversibly inhibits tcu-PA, 
due to formation of a 1:1 molar ratio of SDS-stable covalent complexes. PAI-1 is also a 
rapid physiologic inhibitor of tissue-type plasminogen activator (t-PA), and can inactivate 
Pn in vitro (Declerck, De Mol et al. 1992).     
1.3.2. Internalization of u-PAR and clearance of u-PA-PAI-1  
The u-PA-PAI-1 covalent complex is found in solution and bound to the cell surface.  
The enzyme-inhibitor complex is cleared via protein degradation. u-PAR plays a 
secondary role in aiding the clearance of the u-PA-PAI-1 complex by forming a tertiary 
complex, u-PAR:u-PA-PAI-1.  The receptor-bound protease-serpin complex is cleared 
from the cell surface by the endocytic receptor, α2-macroglobulin receptor / low density 
lipoprotein receptor-related protein (LRP) (Nykjaer, Kjoller et al. 1994; Conese, Nykjaer 
et al. 1995; Czekay, Kuemmel et al. 2001).  LRP, also known as LRP1, is a member of 
the LDL receptor family and is a multifunctional scavenger that plays a role in lipid 
metabolism.  LRP internalizes target ligands via clathrin-mediated endocytosis with 
subsequent ligand clearance and degradation. LRP is essential for survival, as 
homozygous knock-out mice are not viable (Jedrychowski, Gartner et al. 2010)).  LRP is 
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a transmembrane protein with molecular weight of 600 kD that contains a light chain (85 
kD) and a heavy chain (515 kD), which contains four clusters of cysteine-rich 
complement repeats and a cytoplasmic tail with NPxY motifs.  The receptor interacts 
with at least 30 different ligands, including t-PA-PAI-1, u-PA-PAI-1, fVII:TF:TFPI, 
integrins, and u-PAR (Kounnas, Church et al. 1996; Rodenburg, Kjoller et al. 1998; 
Zhang, Sakthivel et al. 1998).  The major ligand-binding regions are within either cluster 
II or IV. 
Receptor-associated protein (RAP) is a molecular chaperone for LDLR family 
members. It is a 39 kD membrane anchored protein localized to the endoplasmic 
reticulum and is recognized by LRP clusters I and III (Horn, van den Berg et al. 1997).  
RAP antagonizes the binding of all other known LRP ligands, thus preventing premature 
association of ER proteins to the receptor.  Recombinant soluble RAP has served as an 
invaluable tool in the study of LRP biology, since it also blocks the binding of ligands on 
the cell surface (Williams, Ashcom et al. 1992). 
u-PA-PAI-1 complexes are recognized by LRP, but pre-binding to u-PAR is required 
for internalization and degradation to occur, unless u-PA-PAI-1 complexes are present at 
high concentrations.  The quaternary complex, once formed, rapidly undergoes clathrin-
mediated endocytosis. Internalization results in movement of the quaternary complex 
from the cell-surface into early-endosomes (Czekay, Kuemmel et al. 2001).  Within the 
early-endosomes, the u-PA-PAI-1 complexes dissociate from both u-PAR and LRP, and 
are directed into late-endosomes. The u-PA-PAI-1 complexes are transferred to end-
lysosomes for degradation, while u-PAR and LRP resurface (Nykjaer, Conese et al. 
1997).  u-PAR has only been identified in late lysosomes in one study (Nykaer 1998).   
9 
 
Bridging via the u-PA-PAI-1 complex appears to be primarily responsible for the 
tight interaction between u-PAR and LRP, although one study found a direct interaction 
between the endocytic receptor and D3 of u-PAR.  Because internalization decreases the 
concentration of u-PAR on the cell-surface, it provides an efficient mechanism for 
immediate downregulation of the cell surface proteolytic processes mediated by the u-
PA:u-PAR complex.  Receptor internalization may also assist cells in modulating several 
key functions such as adhesion and migration, since u-PAR interacts with high affinity to 
the extracellular matrix by Vtn (Nykaer 1998; Cao, Lawrence et al. 2006). 
1.3.3. Resurfacing and receptor degradation  
Recent studies show that u-PAR and LRP are internalized and recycled in the same 
vesicles.  LRP-mediated internalization can result in the redistribution of u-PAR to focal 
adhesion sites, where u-PAR subsequently aids in the activation of proteolysis and/or 
engagement of cell-matrix contact (Czekay and Loskutoff 2009).  u-PAR can also be 
internalized and recycled in specialized lipid rafts called “caveolae” (Cortese, Sahores et 
al. 2008).  Caveolae are flask-shaped invaginations of the plasma membrane containing 
the protein caveolin, a 22 kD protein (Rothberg, Heuser et al. 1992) that plays a role in 
signaling, migration, cholesterol uptake, and internalization via a non-clathrin mechanism 
(Stan 2007).  Clustering of u-PAR to calveolae augments pericellular Pg activation and a 
wide array of cellular signaling (Stahl and Mueller 1995; Wei, Yang et al. 1999; Cavallo-
Medved, Mai et al. 2005). u-PAR also clusters with β1-integrins in the presence of 
caveolin, promoting kinase recruitment, ERK signaling, and cell adhesion (Wei, Yang et 
al. 1999; Tang, Burke et al. 2009)   
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1.4.Non-proteolytic role of u-PAR 
u-PAR interacts with several proteins [e.g. Vtn, integrins, and epidermal growth 
factor receptor (EGFR)], and strongly influences cell adhesion, signaling, proliferation, 
migration and cell differentiation in both normal and neoplastic cells (Wei, Tang et al. 
2007; Madsen and Sidenius 2008). u-PAR-mediated activities modulate physiologic 
processes such as wound healing, inflammation, and stem cell mobilization, as well as 
pathophysiological processes such as metastasis and tumor invasion.  More recently, in 
vivo studies showed that u-PA:u-PAR interaction suppresses fibrin-associated chronic 
inflammation (Connolly, Choi et al. 2010). 
Since u-PAR lacks a transmembrane domain and a cytoplasmic domain, it is unable 
to signal directly. Thus, GPI-anchored proteins, such as u-PAR, interact with 
transmembrane proteins through lateral binding to affect intracellular signaling (Korty, 
Brando et al. 1991; Stefanova, Horejsi et al. 1991; Anderson 1994)  The cis-ligands for u-
PAR are EGFR, LRP, caveolin, integrins, and FPRL1 (Table I).  As discussed above, the 
binding of u-PA to u-PAR leads to receptor activation and promotes the interaction with 
other cell-surface or matrix proteins (Table I). Liberation of u-PAR from its GPI-anchor 
by proteases or phospholipases, and the subsequent generation of soluble u-PAR, shifts 
its role from a receptor to that of a soluble ligand capable of initiating ERK and FAK 
signaling events (Piccolella, Festuccia et al. 2008). 
1.4.1. Adhesion 
Cell surface u-PAR is found in close proximity to proteins that mediate adhesion and 
expression of u-PAR increases cellular adhesion.  Direct interactions between u-PAR, 
Vtn, and members of the integrin superfamily have been extensively investigated in a 
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wide variety of cell types (i.e. H1299, MCF-7, MDA-MD-231) (Dass, Ahmad et al. 
2007).  u-PAR-dependent adhesion is regulated by u-PA, PAI-1, and the endocytic 
receptors, utilizing u-PA-induced u-PAR activation and endocytosis-mediated 
downregulation to control the affinity and availability of cell-surface u-PAR for its 
binding partners. 
Vitronectin is primarily synthesized in the liver as a 456-residue single-chain 
polypeptide and 19-residue signaling sequence.  It predominantly circulates in human 
plasma as a 75 kD protein.  The N-terminal 44-residue is known as the somatomedin B 
domain (SMB).  The SMB domain of Vtn binds to u-PAR and PAI-1 in a mutually 
exclusive manner. At the C-terminal of the SMB domain is the RGD sequence that is 
critical to the binding of Vtn with integrins and mediates adhesion (Chillakuri, Jones et 
al. 2010).  An area adjacent to the RGD region contains two sulfated tyrosines that bind 
extracellular matrix (ECM) proteins, such as collagen.  Near the C-terminus, spans basic 
residues that binds heparin and other glycosaminoglycans, and may contain a lower-
affinity, secondary binding site for PAI-1. 
u-PA promotes the binding of Vtn to u-PAR (Madsen, Ferraris et al. 2007). The 
dissociation constant for u-PAR and Vtn in the absence of u-PA is approximately 1.9 
µM.  When u-PA is pre-bound to u-PAR, the affinity for Vtn increases about 4-fold to 0.4 
µM.  In vitro, the u-PA effect is nullified when u-PAR is over-expressed, potentially due 
to avidity (Wei, Waltz et al. 1994; Wei, Lukashev et al. 1996; Cunningham, Andolfo et 
al. 2003).  Vitronectin binding does not alter the affinity of u-PAR for u-PA.   
Recent mutational analysis of the interaction between u-PAR and Vtn showed that 
this interaction is distant from the u-PA binding site of u-PAR. Because proteolytic 
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removal of D1 disrupts the interaction between Vtn and u-PAR (Sidenius and Blasi 2000), 
cleavage of D1 can mediate cell-adhesion (Montuori, Carriero et al. 2002).  Alanine 
scanning analysis identified five residues in u-PAR that contribute to Vtn binding. These 
consist of three residues from D1 (Trp32, Arg58 and Ile63) and two residues from the linker 
region (Arg91 and Tyr92) (Gardsvoll and Ploug 2007; Madsen, Ferraris et al. 2007).  
Crystal structures of the ATF:u-PAR:SMB complex indicate that SMB interacts with the 
D1-D2 region of u-PAR, which is found on the opposite side of the u-PA binding cavity.  
Vtn binds PAI-1 with high affinity (KD < 100nM) at a site that adjacent to the u-PAR 
binding site.  Because the binding sites on Vtn for u-PAR and PAI-1 are located so 
closely together, PAI-1 can effectively block the association of the receptor with Vtn, 
thus nullifying the contribution of this interaction to cellular adhesion (Preissner, Kanse 
et al. 1999). 
Adhesion is also mediated through the interaction of u-PAR and integrins. Integrins 
are ubiquitous transmembrane adhesion molecules that are involved in cell-cell or cell-
ECM contacts. Integrins are α/β heterodimeric receptors that interact with many 
extracellular matrix and cell-surface proteins and regulate cellular adhesion, migration, 
growth, survival and differentiation.  u-PAR and integrins co-localize at focal adhesion 
points at the leading edge of migrating cells (Estreicher, Muhlhauser et al. 1990).  
Binding of u-PAR to integrins is distinct from that with Vtn or u-PA, since peptides 
blocking integrin:u-PAR interactions do not affect either the formation of u-PAR:Vtn 
complexes or u-PAR:u-PA complexes (Simon, Wei et al. 2000). However, the manner in 
which u-PAR binds to integrins remains unknown. 
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u-PAR interacts with β1, β2 and β3 integrins, but associates most strongly with 
members of the β1 family (Wei 1996). On 293 cells, expression of u-PAR redirects 
adhesion from a β1 integrin-fibronectin mechanism to a u-PAR:Vtn mechanism (Wei 
1996)  The β2 family plays an important role in inflammation, specifically in leukocyte 
migration and adhesion.  u-PAR, in the presence of u-PA, co-localizes with αvβ3 in the 
membrane ruffles of smooth muscle cells (Degryse, Resnati et al. 1999), the presence of 
Vtn promotes clustering of u-PAR and αvβ3 (Stepanova and Tkachuk 2002).  Expression 
levels of u-PAR and αvβ3 appear to be co-regulated, and migration can be inhibited by 
either anti-u-PAR or anti-αvβ3 antibodies (Degryse, Resnati et al. 1999). 
1.4.2. Signaling 
Interaction of u-PAR with a number of proteins can activate kinase cascades, these 
include integrins, epidermal growth factor receptor (EGFR), the GPCR FPR-like 
receptor-1 / lipoxin A4 receptor (FPRL-1), caveolin, gp130, and kininogen (Smith and 
Marshall 2010).  This wide signaling specificity is attributed to the dynamic composition 
of the u-PAR-receptor signaling complex (Jo, Thomas et al. 2003). A recent crystal 
structure indicates that a large interface on u-PAR is available for interaction with these 
proteins (Huai, Mazar et al. 2006). 
Though much has been uncovered on u-PAR’s structure-function relationships, the 
mechanism by which u-PAR accomplishes intracellular signaling remains unclear. u-
PAR affects cellular behavior and functions in ways that are both u-PA-dependent and -
independent.  u-PAR contains a unique linker region between D1 and D2 that is sensitive 
to proteolysis by tcu-PA, Pn, and matrix metalloproteases (MMP) (Hoyer-Hansen, Ronne 
et al. 1992; Hoyer-Hansen, Ploug et al. 1997; Montuori, Rossi et al. 1999).  u-PA-
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mediated cleavage of u-PAR in the linker region is only observed in GPI-anchored u-
PAR since it requires the enzyme to be concurrently bound to a second membrane-bound 
u-PAR molecule, facilitating protease-substrate recognition (Hoyer-Hansen, Pessara et al. 
2001). This trans-cleavage dissociates D1 from the rest of the anchored receptor that 
results in a loss of affinity for u-PA and Vtn. The generation of a new N-terminal region 
in u-PAR exposes the previously buried chemotactic epitope, 88SRSRY92, which leads to 
changes in migration and signaling (Fig. 1.1.3) (Fazioli, Resnati et al. 1997).  A 
pentapeptide, based on the chemotactic epitope, induces signaling events and reduces 
adhesion (Gargiulo, Longanesi-Cattani et al. 2005).  While receptor cleavage is a 
powerful trigger for changes in cellular behavior, alterations in proliferation, adhesion, 
migration, and differentiation can also be induced by enzymatically inert forms of 
urokinase, such as the zymogen scu-PA, chemically inactivated tcu-PA, and ATF.  These 
observations led to the hypothesis that binding of u-PA to u-PAR leads to conformational 
changes that increase interactions with the adapter protein listed above, ultimately 
enhancing signaling events (Mukhina, Stepanova et al. 2000). 
Since the effects of u-PA-binding and u-PA-mediated cleavage on u-PAR-dependent 
cellular events are at least partially overlapping, the physiological relevance of these two 
modes of u-PAR activation has been difficult to delineate.  The roles of u-PAR in cell 
signaling have also been difficult to dissect because the cellular response varies 
depending on the ligand to which u-PAR is exposed, the cell line studied, and the make-
up of the membrane receptor signaling complex. Despite these challenges, several 
different u-PAR-influenced signaling pathways have been isolated (Table II), including 
ERK/MAPK, Src, GPCR, and JAK/STAT. 
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ERK/MAPK signaling activation is required for cell differentiation, adhesion, 
migration, and proliferation.  u-PAR-dependent ERK activation occurs primarily though 
non-exclusively via EGFR.  EGFR activation simultaneously upregulates ERK while 
down-regulating the pro-apoptotic p38 mitogen-activating protein kinase pathway, thus 
promoting cell proliferation. Over-expression of u-PAR activates α5β1 integrins and 
EGFR, sustains ERK activity, and upregulates genes necessary for cells to enter S-phase 
to promote cell growth (Weber, Hu et al. 1997; Murphy, Smith et al. 2002; Jo, Thomas et 
al. 2003). The relationship between u-PA:u-PAR in signaling also plays a role in 
apoptosis. u-PAR has an anti-apoptotic effect in MDA-MB-231 breast cancer cells; α-u-
PA antibody leads to a decrease in ERK phosphorylation and an increase in apoptosis 
(Ma, Webb et al. 2001; Alfano, Iaccarino et al. 2006). ERK activation is necessary for 
expression of both u-PA and u-PAR. This positive-feedback loop shows the tight 
regulation found in the u-PA:u-PAR system, where the maintenance of ERK activation 
can lead to suppression of apoptosis and promote cancer progression.       
u-PAR can activate the GPCR signaling pathway via exposure of the receptor’s 
chemotactic region since u-PA has no effect on signaling events when FPRL1 is 
expressed in the absence of u-PAR (Resnati, Pallavicini et al. 2002; Jo, Thomas et al. 
2003)   Cleaved su-PAR behaves only as a partial agonist similar to, but not as effective 
as, its membrane bound u-PAR:u-PA counterpart. These studies suggest that the 
signaling potential of u-PAR is dependent on the form that is present on the cell: either 
unliganded/latent, u-PA–bound/active, or cleaved/active.  
u-PAR-dependent β1 integrin signaling leads to activation of Src kinase and focal 
adhesion kinase (FAK).  Activation of Src family tyrosine kinases is required for 
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adhesion mediated by the fibronectin and Vtn receptors, α5β1 integrin and αVβ5 integrin, 
respectively.  In addition, phosphorylation of FAK leads to Src-binding and promotes 
cellular proliferation, migration, and survival (Giancotti and Ruoslahti 1999; Aguirre 
Ghiso 2002; Mitra and Schlaepfer 2006).  u-PAR-mediated enhancement of FAK 
activation is u-PA-dependent, and this is accompanied by increased co-
immunoprecipation of u-PAR and β1 integrins, which is consistent with the hypothesis 
that u-PA induces a conformational change in its receptor that augments integrin-binding 
(Yebra, Goretzki et al. 1999; Nguyen, Webb et al. 2000). 
u-PAR can also be co-immunoprecipitated with JAK/STAT proteins (Koshelnick, 
Ehart et al. 1997).  In smooth muscle cells (SMC), the association of JAK1 and u-PAR 
phosphorylates STAT1, which in turn translocates to the nucleus and alters gene 
expression (Dumler, Weis et al. 1998). The activation of this signal transduction pathway 
may be involved in cell migration regulation.  For pathways involving at least two of the 
STAT proteins, STAT3 and STAT5b, activation by u-PA-bound u-PAR is independent of 
u-PA’s proteolytic activity (Jo, Thomas et al. 2005; Shetty, Rao et al. 2006). 
1.4.3. Cell migration 
Cell migration involves a complex balance between focused proteolysis (the dynamic 
interaction with extracellular matrix proteins), and the ability to reorganize the 
cytoskeleton.  The proteolytic activity of the u-PA/u-PAR system aids in matrix invasion 
and tissue remodeling.  As discussed previously, the u-PA-dependent activation of u-
PAR promotes lateral binding to several molecules that can induce signaling pathways, 
leading ultimately to changes in migration and proliferation.   In vitro studies implicate 
several signaling pathways in u-PAR-mediated cell migration. These include 
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ERK/MAPK, tyrosine- and serine-protein kinases, FAK, and Src. Ongoing studies 
continue to identify new participants.   
The pro-migratory effects observed with u-PAR are specific to individual cell types 
and ECM components. Accumulating evidence suggests that integrin activation is 
involved in u-PAR-mediated migration, cell adhesion, proliferation, and cell survival 
(Ossowski and Aguirre-Ghiso 2000; Chapman and Wei 2001).  In leukoctyes, u-PAR-
mediated migration involves β1 and β2 integrins and occurs in a manner dependent on the 
concentration of u-PA (Gyetko, Todd et al. 1994; Aguirre Ghiso, Kovalski et al. 1999; 
Liu, Aguirre Ghiso et al. 2002; Montuori, Carriero et al. 2002).  u-PA-induced 
cytoskeletal reorganization and cell migration is halted in the presence of signaling 
pathway inhibitors such as pertussis toxin (PTX), calphostin, and PD98059, 
demonstrating the involvement of GPCR, PKC, and MEK1, respectively.  In MCF-7 
cells, increased u-PAR occupancy by u-PA activates ERK1/2 and leads to migration 
mediated through the JAK kinase family (Nguyen, Hussaini et al. 1998). 
The induction of pathways may also depend on the manner in which u-PAR is 
activated.  Chymotrypsin-cleaved su-PAR exhibits pro-chemotactic activity similar to 
that of u-PAR bound by inactive u-PA in p56/59hck activation and signals via the 
FRPL1/LXA4R (Resnati, Pallavicini et al. 2002). Non-cleavable u-PAR enhances 
migration via signaling pathways differently from those of the wild-type receptor 
(Mazzieri, D'Alessio et al. 2006).  These mutations display the inability to activate ERK 
or engage FRPL1 and GPCR, leaving EGFR as the major cell-surface receptor induced 
by non-cleavable u-PAR (Mazzieri, D'Alessio et al. 2006).  
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1.4.4. Cell proliferation 
Signaling responses mediated via u-PAR also impact cell proliferation. The 
proliferative effect of u-PAR correlates with the expression levels in tumor cells, and is a 
strong predictor of malignant behavior. u-PAR:integrin interactions promotes neoplastic 
cell proliferation, tumor growth, and invasion (Ossowski 1988; Liu, Aguirre Ghiso et al. 
2002).  Proliferation of u-PAR-expressing cells involves the activation of the 
ERK/MAPK pathway and deactivation of the p38 MAPK pathway (Liu, Liu et al. 1997). 
In HEp3 cells, high expression levels of u-PAR leads to tumor growth whereas the down-
regulation of u-PAR causes cell dormancy (Yu, Kim et al. 1997).  ERK activation in u-
PAR-expressing HEp3 cells is dependent on the α5β1-integin:u-PAR interaction, which is 
optimal when u-PA is bound to u-PAR and Fn is bound to α5β1-integin.   
u-PAR cross-talks with growth factor receptors such as EGFR and PDGFR (Liu, 
Aguirre Ghiso et al. 2002; Kiyan, Kiyan et al. 2005).  EGFR is known to interact with u-
PAR and remains activated when u-PAR is overexpressed. The regulation of proliferation 
by u-PAR requires ERK activation, which is FAK-dependent but EGFR-ligand 
independent (Aguirre-Ghiso, Liu et al. 2001)).  EGFR signaling is α5β1 integrin 
dependent and leads to constitutive ERK pathway activation which is necessary for in 
vivo growth.  High levels of u-PAR create a positive feedback loop, with high ERK 
activity inducing expression of u-PA and u-PAR (Lengyel, Stepp et al. 1995).  EGFR is 
the most influential receptor leading to ERK activation, and is essential for u-PAR-
initiated ERK up-regulation (Jo, Thomas et al. 2003).  In the absence of EGFR, the 
presence of u-PA leads to a G-protein dependent migration (PTX sensitive) migration 
(Resnati, Guttinger et al. 1996; Fazioli, Resnati et al. 1997; Degryse, Orlando et al. 
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2001).   u-PAR can also cross-talk with PDGFR in vascular smooth muscle cells, wherein 
activation of u-PAR by u-PA-binding induces PDGF-independent PDGFR-beta 
phosphorylation and cell proliferation (Kiyan, Kiyan et al. 2005). 
As expected, down-regulation of u-PAR in cell lines affects signaling pathways 
involved in the cell cycle.  Decreases in u-PAR expression lead to inhibition in invasion, 
adhesion, proliferation and migration (D'Alessio, Margheri et al. 2004; Dass, 
Nadesapillai et al. 2005).  The use of antisense oligodeoxynucleotide (asODN) leads to a 
dramatic decrease in ERK1/2 activation in melanoma cells (D'Alessio, Margheri et al. 
2004) and a dramatic decrease in FAK/JNK/Jun activation in prostate cancer cells 
(Margheri, D'Alessio et al. 2005). u-PAR down-regulation in vivo by u-PAR anti-sense 
ODN or short-interference RNA (shRNA) reduces tumor growth and metastases in at 
least two different cancers (i.e. Meningiomas and MDA-MB-231) (Mohan, Lakka et al. 
1999; Lakka, Rajagopal et al. 2001; Wang, Ma et al. 2001; D'Alessio, Margheri et al. 
2004; Gondi, Lakka et al. 2004; Dass, Nadesapillai et al. 2005; Margheri, D'Alessio et al. 
2005; Kunigal, Lakka et al. 2007; Tummalapalli, Gondi et al. 2007).  
1.4.5. Cell apoptosis 
Deregulation of apoptosis and enhancement of proliferation is crucial for neoplastic 
cell survival.  Cell death via apoptosis is tightly regulated in normal cells, whereas in 
cancer cells, this regulation has been interrupted by as yet poorly defined mechanisms. 
Recent studies of u-PAR down-regulation show an increase in cellular apoptosis, whereas 
over-expression promotes cellular growth.  u-PAR downregulation is associated with a 
heightened response to TNF-α mediated ligand-induced apoptosis (Alfano, Franco et al. 
2005), while use of shRNA u-PAR in glioblastoma cells increases caspase-mediated 
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apoptosis (Yanamandra, Konduri et al. 2000). In HEK293 cells, expression levels of u-
PAR are positively correlated with resistance to apoptosis after ECM detachment. 
Downregulation of u-PAR leads to substantial cell death via apoptosis by p53 activation, 
which is independent of ERK or FAK signaling in melanoma cells (Besch, Berking et al. 
2007). ERK1/2 activation is enhanced, with a decrease in p38 (negative growth regulator) 
activation, leading to a halt in apoptosis and promotion of cell proliferation (Aguirre-
Ghiso, Liu et al. 2001; Liu, Aguirre Ghiso et al. 2002). When cells undergo apoptosis, the 
presence of u-PA-bound to u-PAR reverses events leading to cell death (Alfano, 
Iaccarino et al. 2006).   In mesangial cells, the u-PA/u-PAR system regulates cell survival 
and apoptosis via a stimulus-specific manner that signals through BAD (bcl-2/bcl-x 
antagonist causing cell death) (Tkachuk, Stepanova et al. 1998). These data suggest that 
u-PAR acts as a survival factor. 
1.5. The role of u-PAR in cancer 
Malignancy is a function of the ability of tumor cells to invade tissue spaces and 
metastasize. Clinical studies associate the Pg activation cascade with a poor prognosis in 
breast cancer (Janicke, Schmitt et al. 1991), and over-expression of u-PAR in particular 
cell lines correlates with malignancy (Andreasen, Kjoller et al. 1997). It is not surprising 
that u-PAR has a role in cancer since approximately 20 years of studies have 
demonstrated u-PAR’s role in Pg activation, internalization of u-PA-PAI-1 complexes, 
and the activation of signaling pathways. When these functions are improperly regulated, 
they can lead to oncogenic cell transformation, enhanced proliferation, migration, 
invasion, and resistance to apoptosis (Hanahan and Weinberg 2000).  Expression of u-
PAR has been observed in neoplastic cells and tumor-associated cells from ovary, colon, 
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lung, breast, endometruim, macrophages, endothelial cells, and ﬁbroblasts, suggesting 
that u-PAR might be a useful therapeutic target (Mazar 2001; Wang 2001; Ge and 
Elghetany 2003; Sidenius and Blasi 2003; Mazzieri and Blasi 2005).  The proteolytic role 
of the u-PA/u-PAR system modulates cell invasion and metastasis via its ability to 
disrupt the ECM, and promote adherence (Carmeliet 2000; Jain and Carmeliet 2001). In 
patients with colon and breast cancer, high levels of u-PAR correlates with metastasis and 
poor outcome (Dano K., Behrendt et al. ; Ge and Elghetany 2003). u-PAR over 
expressing cells tend to be located at the leading outer edge of tumors and may provide 
enhanced angiogenesis and infiltration of surrounding normal tissues (Skriver, Larsson et 
al. 1984; Yamamoto, Sawaya et al. 1994; Lindberg, Larsson et al. 2006).   
The ability of u-PAR to interact with many ligands and membrane-anchored partners 
plays a key role in cell-cell interaction and cytoskeleton rearrangement (Table I).  For 
instance the interaction between u-PAR and integrin induces cell signaling events that 
can be optimal for growth, invasion and dissemination of tumor cells.  The broad range of 
potential ligands and interactions for u-PAR and integrins may represent useful 
therapeutic targets because of the significance of downstream signaling events (Degryse 
2011).   
Other strong prognostic markers for survival are the presence of su-PAR and the 
cleavage products D2-D3 and D1 in the plasma of cancer patients. The soluble and cleaved 
form of u-PAR has been found in the fluid of human malignant ovarian cysts, the urine of 
cancer patients and also blood from patients with myeloid leukemia (Wahlberg, Hoyer-
Hansen et al. 1998; Mustjoki, Sidenius et al. 2000; Sidenius, Sier et al. 2000). 
Proliferation of cancer cells can be interrupted by reducing the available intact u-PAR via 
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cleavage and dissociation of D1.  On the other hand, cancer cells derived from anaplastic 
thyroid carcinoma and PMA-stimulated U937 cells often express a form of u-PAR that is 
heavily glycosylated and confers resistance to cleavage by tcu-PA (Picone, Kajtaniak et 
al. 1989; Montuori, Rossi et al. 1999).  There seems to be a correlation between increased 
glycosylation, resistance to tcu-PA cleavage, and tumor aggressiveness in various types 
of thyroid tumor cells, suggesting that tight regulation of u-PAR is essential to maintain a 
balance between pericellular proteolysis, cell signaling, and downstream effectors.   
Measurement of u-PA, u-PAR and PAI-1 is useful in predicting patient outcome.  
Quantitative immunoassays have been developed to measure levels in both solid tumors 
and in blood (Pedersen, Brunner et al. 1994).  Levels of circulating u-PAR in blood 
correlate with expression levels on solid tumors but it seems that both can predict 
outcome. Elevated quantities of u-PAR in breast tumor tissue indicated a poor relapse-
free survival and overall survival (de Witte, Foekens et al. 2001).  There are some 
setbacks in the quantitation of u-PAR levels for prognostic value since its prognostic 
indicator is diminished by the addition of PAI-1 to the multivariate model (Grondahl-
Hansen, Peters et al. 1995).  However, Christensen et al., imply that a more homogenous 
sample, blood, should be taken while measuring the levels of u-PAR.  These results were 
reproduced in colorectal cancer by analyzing the levels of su-PAR in plasma samples 
(Stephens, Nielsen et al. 1999; Fernebro, Madsen et al. 2001; Riisbro, Christensen et al. 
2005).  In non-small cell lung cancer, u-PAR D1 levels were determined rather than intact 
su-PAR levels, with the reasoning that cleavage reflects an active plasminogen activation 
cascade and should correlate with a better prognosis.  These studies show that u-PAR has 
potential as a biomarker and therapeutic target but more studies need to be performed.   
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1.6. Overview of project 
u-PAR has been widely shown to be involved in cancer, angiogenesis and 
inflammatory diseases.  The evidence for the roles of u-PAR in neoplasia and the 
multiple regulatory mechanisms associated with u-PAR suggests that cleavage of the 
receptor may be important for regulation of specific cell functions.  However, the 
complexity of u-PAR interactions makes it extremely difficult to associate individual u-
PAR forms with specific u-PAR functions. Many of the receptor’s functions have been 
hypothesized to be associated with both u-PA binding and a potential conformational 
change in the receptor.  However, it has been difficult to delineate whether the 
downstream effects of u-PAR activation are regulated by a cell-surface bound u-PA 
through u-PAR, by a u-PA induced conformational change in u-PAR, or by the 
generation of cleaved u-PAR via tcu-PA.  All three circumstances require the presence of 
tcu-PA.   
In this work, we created a mutant form of u-PAR that allows for better discrimination 
between the potential mechanisms of action of u-PAR. Since various forms of u-PAR 
have been widely used that affect cell function and cancer progression, we chose to 
explore the importance of receptor cleavage in Pg activation, clearance of u-PA-PAI-1 
complexes, cell migration, receptor signaling and cellular growth.  In order to isolate a 
single receptor form, we exploited the two u-PA cleavage site creating a mutant cleavage 
resistant u-PAR (cr-uPAR) that confers resistance exclusively to tcu-PA associated 
cleavage.  The differences between cr-uPAR and wt u-PAR allows us to discriminate 
between the functions previously linked to both the u-PA-bound u-PAR and the cleaved 
forms of u-PAR.  This mutant allowed us to identify a potential regulatory role for intact 
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u-PAR.  We show that cr-uPAR closely interacts with LRP. This gain of function appears 
to regulate clearance of complexes bound and its re-surfacing. It also promotes u-PAR-
dependent cell migration.   
In addition, exposure of the chemotactic epitope in the linker region of u-PAR is a 
potential link in receptor regulation.  u-PAR’s interaction with lateral cell-surface bound 
molecules may regulate migration, proliferation, adhesion and apoptosis.  Our goal was 
to identify the non-proteolytic functions of u-PAR when a prominent intact receptor is on 
the cell-surface that is u-PA-independent.  The presence of u-PAR appears to contribute 
to a delicate balance in cell functions.  If this balance is tilted toward a highly active 
receptor, we hypothesized that the cell might gain oncogenic features similar to those 
observed in cells expressing a cleavage resistant u-PAR (ARO cells).  Our novel tcu-PA 
cleavage resistant receptor has a direct effect on internalization, created through direct 
binding to LRP that is independent of u-PA-PAI-1 complex binding.  We also 
demonstrate that cr-uPAR has functions that correlate with the highly aggressive thyroid 
carcinoma ARO, with enhanced signaling, migration, proliferation and apoptosis.    
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1.7  Figures and Tables 
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Table I: Functional binding partners of u-PAR 
 
Functional 
Group 
Binding  
Partners 
Cell  
Function 
Reference 
GPI-anchored 
receptor 
 
u-PAR Plasminogen activation, 
pericellular proteolysis, 
adhesion, migration, 
proliferation 
 
Blasi et al. 1990, 
Cohen et al. 1991, 
Ellis et al. 1999, 
Mazar et al. 2008, 
Smith et al. 2010 
Serine protease 
 
scu-PA/ tcu-PA 
 
Plasminogen activation, 
adhesion, migration, 
proliferation 
 
Patthy L et al. 
1985,  Cubellis et 
al. 1986 
Inhibitory 
complex  
tcu-PA-PAI-1 Inhibition of plasminogen 
activation,  
Inhibition of u-PA dependent 
functions, Internalization 
 
Czekay et al. 2001, 
Binder et al. 2007 
Extracelular 
matrix protein 
 
Vitronectin 
 
Adhesion, 
Migration 
Madsen et al. 2007, 
Deng et al. 1996 
Integrins α3β1, α4β1, α5β1, 
α6β1, α9β1  
αMβ2, αLβ2, αXβ2 
αvβ3, αvβ5, αvβ6 
  
 
Adhesion, 
Migration 
Chapman et al. 
1999, Tarui et al. 
2003 
Receptor protein 
tyrosine kinases 
 
EGFR, PDGFR, IGF-
1-R 
Proliferation,  
Migration 
Mazzieri et al. 
2006, Schiller et al. 
2009 
Endocytic receptor 
 
LRP, LRP1B  
 
Internalization 
 
 
 
Czekay et al. 2001, 
Conese et al. 1995, 
Godar et al. 1999 
VLDL-R 
Mannose-6-
phosphate receptor 
UPARAP 
Scaffolding Caveolin Signaling 
 
Chapman et al. 
1999, Wei et al. 
2001 
Cytokine Gp130 Migration 
 
Shushakova et al. 
2005, Liang et al. 
2003 
Adhesion L-selectin Adhesion 
 
Petty et al. 2001 
Seven-
transmembrane 
domain receptor 
FRPL1, FPR, FPRL2 Migration Mazzieri et al. 
2006, Resnati et al. 
2002 
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CHAPTER 2. MATERIALS AND METHODS  
2.1. Materials  
Scu-PA was a kind gift from Dr. Jack Henkin (Abbot Labs, Rockford IL).   Active 
tcu-PA was generated by incubating scu-PA with Pn-sepharose beads, as previously 
described (Manchanda and Schwartz 1991). Pg, Pn and chymotrypsin were purchased 
from EMD Bioscience (San Diego, CA).  Soluble u-PAR (su-PAR) was a kind gift from 
Dr. Andrew Mazar (Attenuon, San Diego, CA).  The monoclonal antibodies directed 
against the C-terminus of LRP, 11H4, and RAP were kind gifts from Dr. Dudley 
Strickland (Univ. of Maryland, MD).  The SMB domain of Vtn was a kind gift from Dr. 
Michael Ploug (Finsen Lab, Denmark). Peptide 7 (AEPVYQYELDSYLRSYY), peptide 
25 (AESTYHHLSLGYMYTLN) and prothrombin peptide (peptide Pt) were all 
synthesized (Biopeptides, San Diego, CA).  Glu-Gly-Arg Chloromethyl ketone (CMK) 
(EMD Bioscience, San Diego, CA) was used to inactivate tcu-PA (CMK-uPA) (Kettner 
and Shaw 1979). DFP was used, in some instances, to inactive residual u-PA in our scu-
PA as described (Manchanda and Schwartz 1991). Active wt PAI-1 and the stable PAI-
114-1B were kind gifts from Dr. Daniel Lawrence (Univ. of Michigan, Ann Arbor, MI).   
The ECL substrate used for immunoblotting was from Pierce (Rockford, IL) and goat 
α-rabbit HRP antibody and streptavidin-HRP were purchased from Jackson 
Immunoresearch (West Grove, PA).  DMEM, high glucose was purchased from the Cell 
Media facility in UIUC.  Trypsin-EDTA, penicillin/strep, L-glutamine, fetal bovine 
serum (FBS) and RPMI 1640 were purchased from Invitrogen (Carlsbad, CA). G418 
sulfate (Gemini Bio, West Sacramento, CA), Hank’s balances salt solution (HBSS) 
(Invitrogen, Carlsbad, CA), non-enzymatic dissociation buffer (Invitrogen, Carlsbad, 
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CA), HEPES (Lonza), and cyloheximide (CHX) (Sigma, St. Louis, MO) were of highest 
quality available.  PBS -Ca+2/-Mg+2 was made using the standard protocol (Sambrook and 
Russell 2006)  Triton X-100 and deoxycholate were purchased from Sigma.  Sulfo-NHS-
LC-biotin, NHS-S-S-LC-biotin, immobilized Protein G and streptavidin-agarose beads 
(Pierce, Rockford, IL) were used to label and isolate proteins.  Protein concentrations 
were determined using the BCA protein assay (Pierce).  
 
2.2.Methods: 
2.2.1. 
Wild-type human u-PAR cDNA was obtained through RT-PCR of mRNA from U937 
lymphoma cells (CRL-1593.2) (ATCC, Manassas, VA).  The u-PAR cDNA was then 
inserted into pBSIISK(+).  u-PAR variants were generated using the Quikchange® site-
directed mutagenesis kit (Stratagene, La Jolla, CA) and sequenced.  The u-PAR sequence 
was compared to the sequence found in NCBI, NM 002659.  The immediate non-coding 
5’ and 3’ region of u-PAR was mutated to insert EcoRI (5’-
TCGATCGGAATTCCATGGGTCACCCGCCGCTG-3’) and EcoRV (5’-
CTGCATGGATATCCTCAGGTTTAGGTCCAGAG-3’) sites, respectively (Table III).  
Several different mutational combinations were constructed at the two tcu-PA cleavage 
sites in u-PAR, Arg83 and Arg89.  Double point mutation combination to the residues were 
generated as follows: R83A / R89A, R83E / R89E, R83A / R89E, and R83E / R89A.  Single 
point mutations were also generated on the individual residues: R83A, R89A, R83E and 
R89E.  The primary mutant u-PAR used in these experiments was the R83A / R89A, termed 
“cr-uPAR.”  Primers for generating R83A/R89A were 5’-GCA ACT CTG GCG CAG 
CTG TCA CCT ATT CCG CAA GCC GTT ACC-3’, and its complementary set (IDT 
Site-directed mutagenesis of u-PAR variants:  
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Inc, Coralville, IA).  Table III shows all primers used for the generation of all other u-
PAR variants.  The primers that were constructed had a high GC content.  To aid in the 
success of mutation, multiple reactions were performed with increasing concentrations of 
DMSO from 0 - 5%.  The reaction was assembled using 10x reaction buffer, 10 mM 
dNTP, 10 µM of forward primer, 10 µM of reverse primer, 100 ng of wt u-PAR 
pcDNA3.1(+), increasing amounts of DMSO, and 2.5 units of KOD polymerase.  The 
final total volume was brought to 50 µl with ddH2O, and the reaction was layered with 
mineral oil.   
Once the reactions were assembled amplification was initiated with a “hot start” step.  
After the “hot start” step, 25 cycles of the denaturing (30 sec at 94°C), annealing (5 sec at 
65°C), and elongation (6 min at 70°C) steps were performed, followed by a final 
elongation step (10 min at 74°C). Amplified samples were electrophoresed on a 1% 
agarose gel, imaged using a digital camera (Cannon) with UV filter and the 1D Kodak 
imaging system.  Since the goal was to express the u-PAR variants in a mammalian cell 
line, standard subcloning procedures and manufacture’s recommendations were followed 
for the restriction digest. EcoRI and EcoRV digested DNA fragments were inserted into 
the cDNA and ligated the u-PAR fragments into the pcDNA3.1(+) (Invitrogen, Carlsbad, 
CA) plasmid using T4 ligase.  Once the variant u-PAR cDNA sequences were in 
pcDNA3.1(+), the mutations were verified before proceeding (high-throughput 
sequencing and genotyping unit, Univ. of Illinois-Urbana, IL).  All variant u-PAR 
cDNAs were transformed into TG1 cells following isolation for transfection into 
HEK293 (293) cells. 
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2.2.2. 
Two cell lines, HEK293 (293, CRL-1573) and U937, were purchased from ATCC.  
293 transfection of plasmids carrying the cDNA of the u-PAR variants (wt u-PAR, cr-
uPAR, the double point u-PAR mutations, and the single point u-PAR mutations) was 
accomplished using the Superfect® transfection reagent as per the manufacturer’s 
protocol (Qiagen, Valencia, CA).  Transfected 293 cells were cultured in DMEM with 
10% FBS and 400 µg/mL G418.  Cell colony selections were then performed (range 12-
24 colonies per cell line) on all the u-PAR variants, and repeated two weeks after.   
Stable transfection into 293:   
 
2.2.3. Antibody purification:  
Protein A sepharose beads (Protein A Sepharose CL-4B, Pharmacia) were 
equilibrated in 10 ml of NaPO4 pH 8.2 buffer prior to use.  The bead slurry was nutated 
for 10 min at room temperature (RT), following centrifugation for 5 min at 2000 rpm.  
This was repeated a total of five times.  Rabbit serum was adjusted to pH 7.0, and 1 mL 
was added to the Protein A beads, and incubated for 2 h at RT.  The beads were 
centrifuged at 2000 rpm for 5 min, and the supernatant was removed.  The antibody 
bound protein A beads were transferred to a Na3PO4 pre-wet column (Bio-Rad).  The 
eluate was tested for unbound antibody until the absorbance (A280) reached 0. Antibody 
fractions were then eluted using 0.1 M NaCitrate, and the pH adjusted using a 
neutralizing buffer. The two fractions with highest A280 were pooled and examined for 
purity using SDS-PAGE with immunoblotting.  
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2.2.4. u-PAR immunoblotting:  
Cells were lysed for 30 min on ice using RIPA (150 nM NaCl, 50 mM Tris-HCl pH 
7.5, 1% deoxycholate, 0.1% SDS, 1% Triton X-100) buffer with protease inhibitor 
cocktail (Roche).  The total protein content was determined using a BCA assay, so that 
equal quantities of protein were loaded on SDS-PAGE. Gels were typically 10% 
polyacrylamide, unless otherwise specified(Laemmli 1970). Electrophoresis was 
performed at 200 V for 1 h.  The samples were transferred to an activated PVDF 
membrane with 100 V current for 1 h in ice-cold transblotting buffer (25 mM Tris pH 
8.0, 192 mM glycine and 20% methanol) per the manufacturer’s recommendations (Bio-
Rad).  The membranes were blocked for 1 h at RT (alternatively overnight at 4°C) using 
TBS/ 0.01% Tween-20/ 1% gelatin, and then  incubated with polyclonal rabbit anti-
human u-PAR (purified as described above) diluted 1:5000 in TBS/ 0.01% Tween-20/ 
1% gelatin for 2 h at RT.  Excess antibody was removed by repeated washing in TBS/ 
0.01% Tween-20.  The membrane was incubated for 1 h at RT with secondary antibody 
(goat α-rabbit HRP, diluted to 1:5000 in TBS/ 0.01% Tween-20/ 1% gelatin), then 
washed 6 times in TBS/ 0.05% Tween-20.  The presence of the target protein was 
detected using SuperSignal ECL buffer (Pierce).     
 
2.2.5. u-PAR cleavage assay: 
Target cells (1x106 of non-transfected 293, 293 wt u-PAR or cr-uPAR) were 
dissociated using non-enzymatic dissociation buffer, then resuspended in DMEM with 
0.1% BSA (Calbiochem, San Diego, CA).  As a control, 5x106 PMA-stimulated U937 
cells (3-day culture) cells were resuspended in RPMI with 0.1% BSA (Picone, Kajtaniak 
et al. 1989).  Cells were acid-washed once to remove surface-bound proteins by addition 
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of 0.1 M Glycine, 0.15 M NaCl (pH. 3.0) for 3 min at RT followed by neutralization 
using 0.5 M Hepes, 0.15 M NaCl (pH. 7.5) (Manchanda and Schwartz 1991).  Tcu-PA 
was generated from scu-PA as previously described (Manchanda and Schwartz).  
Cells were incubated either with 100 nM tcu-PA or 250 nM Pn for 20 h at 37°C. Cells 
incubated with chymotrypsin at different concentrations (0 nM - 100 nM) were incubated 
for 30 min at 37°C.  Cell membrane proteins were solubilized for analysis with RIPA 
buffer (150 mM NaCl, 50 mM Tris-HCl pH 7.5, 1% deoxycholate, 0.1% SDS, 1% Triton 
X-100) (Wei, Lukashev et al. 1996) and protease inhibitor cocktail™ (Roche, 
Indianapolis, IN).  Cell lysate (5 µgs) was subjected to SDS-PAGE (Pierce, Rockford, IL) 
and equivalent loading of proteins was achieved by quantitating samples using a BCA 
assay (Pierce, Rockford IL).  Samples were immunoblotted using polyclonal rabbit α-u-
PAR and goat α-rabbit HRP. In some instances, purified su-PAR and endogenous u-PAR 
were used for comparison. 
  
2.2.6. Reverse transcriptase PCR: 
Cells (5 x 105) were lysed and homogenized in freshly prepared mixture of 99.4 µM 
β-mercaptoethanol (β2-ME) and Lysis Buffer obtained from the Absolute RNA 
Microprep Kit® (Stratagene).  An equal volume of 70% ethanol was added to the cell 
lysate followed by thorough mixing.  The lysate was transferred into an RNA-binding 
spin column (Absolutely RNA® Microprep Kit, Stratagene), and the unbound portion 
was removed.  Contaminating DNA was removed by treatment with DNase I (1 U/µg of 
RNA) (Invitrogen, Carlsbad, CA) for 15 min at 37°C. Residual DNA was removed with a 
high salt exchange followed by a low salt wash. Afterwards, the RNA bound to the 
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matrix was eluted with 60°C elution buffer.  The concentration of RNA was calculated 
from A280.   
First-strand cDNA was prepared using the StrataScript™ First-Strand Synthesis 
System (Stratagene).  For the control reactions, control mRNA was mixed with either 
oligo(dT) primer (100 ng/µl) or random primer (100 ng/µl).  For the experimental 
reaction, 10 µg of total RNA was combined with random primers (100 ng/µl).  The 
reactions were incubated at 65°C for 5 min then slowly cooled to RT (10 min) for the 
primers annealing to the RNA.    
First-strand cDNA was performed by the addition of 10X first-strand buffer, RNase 
Block Ribonuclease Inhibitor (40 U/µl), 100 mM dNTPs, and StrataScript™ reverse 
transcriptase (50 U/µl) following an incubation at 42°C for 1 h.  The control and 
experimental reactions were incubated at 90°C for 5 min and transferred to 4°C for 
subsequent use in the PCR amplification protocol. 
Amplification of cDNA was performed by assembling the reactions with cDNA from 
the first cDNA strand.  The reaction was assembled using 10X reaction buffer, 10 mM 
dNTP, 10 µM of the ATG forward primer, 10 µM of the TGA reverse primer, template 
cDNA, and 2.5 units of KOD polymerase.  The total volume was brought to 50 µl with 
ddH2O, the reaction centrifuged, then layered with mineral oil.  The set-up of the PCR 
amplification was performed as previously described, following assembly of the 
reactions. The mutations were verified prior to DNA sequencing (high-throughput 
sequencing and genotyping unit, U. of Illinois-Urbana, IL). 
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2.2.7. Flow cytometry: 
U937 (human leukemic monocyte lymphoma) cells, suspended 293 non-transfected 
cells, 293 wt u-PAR cells or cr-uPAR cells were washed three times with PBS to remove 
any Ca+2 and Mg+2 present.  The cell surface ligands were eluted off these various cell 
types as described above. Unbound protein was removed by repeated suspension and 
centrifugation for 5 min at 1200 rpm in PBS.  Cells were resuspended at a final 
concentration of 1x106 cells/ 0.1 ml (U937), or 2x106 cells/ 0.1 ml (293 cell variants), and 
incubated with either polyclonal rabbit α−uPAR (1:250 dilution), normal rabbit IgG 
(1:100 dilution) or PBS (control) for 30 min at 4°C.  Next samples were diluted ten-fold 
with PBS and re-pelleted to remove any unbound antibody.  Cells were then resuspended 
into a final volume of 400 µl, and passed through a 40 µm cell strainer to obtain single 
cell suspension. Samples were run through a flow cytometer (Beckman Coulter Epics) 
which was gated for live cells.    
 
2.2.8. Inactivation of tcu-PA: 
tcu-PA was inactivated by two consecutive incubations (each at RT for 20 min) of 1 
mM ERG-CMK (EMD, San Diego CA) in PBS. To remove the excess EGR-CMK, the 
reaction was dialyzed against six exchanges of PBS.  The degree of enzyme inactivation 
was evaluated by measuring the residual amidolytic activity of tcu-PA against 10 mM 
SpecUK (American Diagnostica, Greenwich CT) at 37°C for 30 min.  
 
2.2.9.  125I protein labeling:  
Glass tubes were coated with 20 µl of 100 µg/ml Iodogen reagent (Pierce, Rockford 
IL) in CH2Cl2, evaporated to dryness under of N2, and stored with desiccation at -20°C. 
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CMK-uPA (50 µg) was incubated with I125 (Perkin Elmer) in an Iodogen-coated tube at 
RT for 4 min.  The reaction was quenched with 5 mM saturated tyrosine and 6 mM KI 
solution.  The quenched reaction was transferred onto a G-25 Sephadex column (BioRad) 
and eluted with TBS.  Excess free radioisotope was removed by dialysis using six 
exchanges of ice-cold TBS. Protein concentration and protein integrity were evaluated by 
TCA precipitation, autoradiography, and Coomassie stained SDS-PAGE analysis.  
 
2.2.10. Competition binding assay: 
Cells (2.5x 104) were seeded in a 24-well microplate and incubated for 14 h at 37°C 
with DMEM/ 10% FCS.  Media was then replaced with freshly made pre-chilled DMEM, 
0.1% BSA, 10 mM Hepes and 10 µg/ml CHX. Cells were pre-chilled for 30 min, 
followed by incubation with 200 nM unlabeled CMK-uPA at 4°C for 30 min.  Cells were 
then incubated with increasing concentrations (0 nM - 100 nM) of I125CMK-uPA for 4 h 
at 4°C. Unbound I125CMK-uPA was removed by washing the cells with PBS.  Cells were 
then lysed in 0.1 N NaOH/1% SDS.  
 
2.2.11. Fibrinolytic assay: 
Fibrinogen was radiolabeled with 125I, and prior to the experiment was clotted in 48-
well microplates as previously described. Either (Manchanda and Schwartz 
1990)dissociated cells (0.1M Tris pH 8.1), U937 cells, or 293 cells expressing u-PAR 
(0.1M Tris-EDTA pH 8.1) were added to the pre-formed I125-fibrin clot.  Cells were 
incubated with 1 nM scu-PA for 30 min at 37°C, after which Pg (4 µg/ml) was added. 
Gamma counts were collected on the samples, and data was analyzed to generate the 
percentage of clot lysis, utilizing scu-PA only as 100% clot lysis (GraphPad Prism). 
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2.2.12. Cell surface bound u-PA in plasminogen activation and inhibition: 
293 cell variants (5x104) were seeded overnight with DMEM/ 10% FCS in 24-well 
microplates.  Cells were washed three times with Hanks’ balanced saline solution 
(HBSS) before the addition of reaction buffer (DMEM with 0.1% BSA) alone or 
preincubated with CMK-tcu-PA, tcu-PA, or chymotrypsin followed by an incubation 
with 10 nM tcu-PA for 30 min at 37 °C.  
Cell surface generation of Pn at 37 °C was monitored with a SpectroMax Gemini XS 
microplate spectrofluorometer (Molecular Devices, Sunnyvale, CA) as described (Ellis, 
Behrendt et al. 1991), with the modification of 56 nM Pg and 600 µM of the Pn substrate, 
H-D-Ala-Leu-Lys-AMC (Bachem, Torrance, CA) in PBS and 0.1% BSA. Excitation and 
emission wavelengths were 360 and 460 nm, respectively.  
Cell samples were pre-incubated with 100 nM CMK-uPA, to block specific binding 
between active tcu-PA and receptor.  The effect of limited proteolysis of u-PAR on its 
ability to support Pg activation was studied by pre-incubating cell samples with either 
100 nM tcu-PA or 100 nM chymotrypsin.   
Pre-formed complexes of tcu-PA and PAI-1 were generated by incubation of 3 µM 
tcu-PA with 7 µM PAI-1 for 30 min at 37°C.  The ability of u-PAR to bind these pre-
formed complexes was tested by treatment of cells with 10 nM u-PA-PAI-1 complexes 
and washed prior to the addition of 10 nM tcu-PA. The ability of u-PAR to allow 
receptor-bound tcu-PA to be inhibited was tested by allowing binding of 10 nM tcu-PA 
followed by a 30 min incubation with 20 nM PAI-1 at 37°C before the addition of Pg and 
Pn substrate. The residual activity of the protease-serpin complex was assayed for 
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amidolytic activity using SpecUK (American Diagnostica, Greenwich CT) for 30 min at 
37°C.   
The rates of Pn generation were determined from parabolic plots of RFU versus time, 
fitted to a second-order polynomial, and then conversion to nanomolar Pn by reference to 
the amidolytic activity of purified Pn using the same fluorogenic substrate (Griffith, 
Breitkreutz et al. 1985; Fiore, Neuenschwander et al. 1992).  
 
2.2.13. Internalization assay:  
Cells (1.5x105) were harvested 18 h prior to labeling. Cell-surface u-PAR was 
biotinylated using 200 µM sulfo-NHS-SS-LC-biotin (Pierce, Rockford IL) as previously 
described (Wu and Gonias 2005). Cells were incubated with or without 10 nM u-PA-
PAI-1 complex for 30 min at 4°C and were subsequently exposed to an increase in 
temperature (37°C) to initiate internalization. At specified times (0 – 30 min) cells were 
treated with 100 mM DTT (Fisher, Pittsburgh, PA) for 3 min at 37ºC followed by lysis in 
RIPA buffer.  For controls, 500 nM RAP was added for each time point and incubated as 
described above. Lysates were exposed to streptavidin-agarose beads followed by  β-ME 
reduction and denaturation to recover biotinylated u-PAR. Total crude cell lysate (10 µl) 
was reduced to quantify the total amount of u-PAR found in the samples.  Samples were 
subjected to SDS-PAGE and detected using polyclonal rabbit α-uPAR (1:5000 dilution), 
washed blot with TBST and followed by goat α-rabbit HRP.   
Alternatively, 293 cells expressing u-PAR were incubated with 10 nM biotinylated 
PAI-114-1B-tcu-PA complex for 30 min at 4°C.  Cells were exposed to 37°C to initiate 
internalization.  At specified times (0 – 30 min), cells were acid washed twice, and then 
lysed in RIPA buffer.  All samples were subjected to SDS-PAGE and detected using 
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streptavidin-HRP (1:10,000) (Pierce, Rockford IL).  Blots were analyzed by densitometry 
using the Kodak 1-D system.  Control samples were prepared as described above and 
incubated with PAI-114-1B-tcu-PA for 30 min at 37°C, except that 500 nM RAP was 
added to each incubation solution.    
 
2.2.14. Receptor recycling assay: 
293 cells (5x104) were seeded with DMEM in 96 black microplates for 18 h at 37ºC 
prior to the experiment.  Cells were then incubated with u-PA-PAI-1 complexes for 30 
min at 4ºC.  Unbound complex was washed off and the cells were incubated at 37ºC from 
0 to 30 min.  After which 10 nM tcu-PA was added for 30 min and further incubated at 
37ºC. The amount of cell-surface u-PAR was measured via the Pg activation assay as 
described above.  Cell surface-associated tcu-PA activity was normalized to the maximal 
amount of tcu-PA activity in the absence of u-PA-PAI-1 complexes.  For the control 
samples, 500 nM RAP was added to all incubation solutions, as described.   
 
2.2.15. Co-immunoprecipitation of u-PAR with LRP:  
Immunoprecipitation experiments were performed as previously described (Czekay, 
Kuemmel et al. 2001).  Suspensions of 1x106 cells (293 wt u-PAR or cr-uPAR), were 
incubated in DMEM with 0.1% BSA only, or with additional 10 nM u-PA-PAI-1 
complexes for 30 min at 4°C.  Parallel samples of cells were incubated with either buffer 
or u-PA-PAI-1 complexes, with the addition of one of the following: 500 nM RAP, 4 µM 
SMB, 4 µM peptide 7, 4 µM peptide 25 or 4 µM peptide Pt.  Treated cells were lysed in 
PBS/ 0.1% Triton-X 100 / 2 mM CaCl2 for 30 min at 4°C.  Lysates were then incubated 
46 
 
with 2.6 µg/ml and 20 µl/ml of mAb 11H4 and immobilized Protein G for 18 h at 4°C.  
Immunprecipitates were subjected to SDS-PAGE.  Samples were immunoblotted using 
polyclonal rabbit α-uPAR antibody (1:5000 dilution) and goat α-rabbit HRP (1:5000 
dilution) (Jackson ImmunoResearch).   The immunoblots were analyzed using Kodak 1D 
and GraphPad Prism software. 
 
2.2.16. Chymotrypsin cleavage assay:  
Cells (2.5x106 cells/ml of 293 wt u-PAR or cr-uPAR) were suspended and incubated 
with DMEM, 0.1% BSA, and 100 µg/ml CHX in the absence or presence of 100 nM 
CMK-uPA for 30 min at 37°C.  This was followed by incubation with 100 nM 
chymotrypsin (Fazioli, Resnati et al. 1997) at 37ºC for 0 to 30 min.  Cells were then 
washed twice with PBS and lysed using RIPA buffer.  Total crude lysate (10 µg) was 
loaded onto 10% SDS-PAGE gels and analyzed for u-PAR following immunoblotting as 
previously described.   
 
2.2.17. Cell morphology: 
Cells (2.5x106) were seeded in DMEM/ 10% FBS on Permanox™-treated slides 
(Nunc) and incubated at 37ºC / 7.5 % CO2 until 50% confluency was reached. On the 
day of the experiment, the cells were treated with 10 µM D-mannosamine or SF DMEM 
for 3 h at 37ºC, washed twice in PBS, and suspended in fresh SF DMEM on a slide. Then 
cells were sealed with a coverslip. Images were obtained with a SPOT camera at 20X and 
40X magnifications. Images were measured by three separate blinds for all cells studied 
and with a minimum of three measurements per cell type.   
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2.2.18. Immunofluorescence: 
Cells were harvested on Permanox™-treated slides (Nunc) as described above. The 
cells were rinsed in PBS followed by fixation with fresh 4% paraformaldehyde for 20 
min. PBS was exchanged for the paraformaldehyde, followed by permeabilization with 
PBS/ 0.1% Triton X-100. Slides were then incubated with 10 nM Alexa488-CMK-uPA, 
Hoechst and Alexa560-Phalloidin (Invitrogen) for 1 h at 4°C. Images were obtained using 
a Spot Camera and a Zeiss Microscope at 40x magnification.   
 
2.2.19. Proliferation assay: 
Cells (2,000-50,000/ well) were seeded with DMEM/ 1% BSA into a 96 well 
microplate to generate a standard curve.  Test wells were seeded at 5,000 cells/well. 
When necessary, 40 µM PD98059 (EMD), and/or 40µM JNKII inhibitor (Cell Signaling) 
were added daily. On the day of experiment, well media was exchanged with fresh 
DMEM/10% FCS. 20 µl CellTiter 96® AQueous One Solution Reagent (Promega) was 
incubated for 1.5 h at 37°C in humidified, 5% CO2 atmosphere.  A490 was measured on a 
Spectramax® microplate reader (Molecular Devices) and converted to cell number using 
the standard curve as a reference.  
 
2.2.20. Dissociation assay: 
Cells (100,000) were grown with DMEM/ 10% FCS in a 24 well plate for 18 h at 
37ºC and 5% CO2, then washed twice with HBSS (Bio-Whittaker).  Cells were then 
incubated at RT for 0 - 30 min with enzyme-free dissociation buffer (Gibco).  Dissociated 
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cells, from each time point, were centrifuged and resuspended in DMEM, 10% FCS (100 
µl).  Resuspended cells were transferred into a 96 well plate and cell counts were 
determined as described in the proliferation assay.  
 
2.2.21. Adhesion assay:  
Untreated wells of a 96 well microplate were pre-coated either overnight at 4°C, or 
for 3 h at 37°C, with 1 µg/ml Vtn or 1% FCS.  Wells were then blocked with PBS/ 0.1% 
BSA for 1 h at 37°C. Previously dissociated cells were added (100,000 / well), then 
incubated for 1 h under normal growth conditions and washed three times to remove non-
adherent cells.  SF DMEM and Cell One™ proliferation reagent was added as previously 
described.  Adherent cells were analyzed and compared to an untreated sample that 
represented the total cell number used to obtain the ratio of bound cells relative to the 
total.  
 
2.2.22. Migration assay:  
Resuspended cells (2x105) were incubated in either the presence or absence of 0.5 nM 
tcu-PA in SF DMEM for 15 min at 37ºC, and then placed on the top portion of 
Transwell™ chambers (Corning, Corning, NY) coated previously with 20% FCS or 10 
µg/ml Vtn.  For serum-coated matrix, the stimulus was performed in DMEM with 10% 
FCS added to the bottom chamber and incubated for 2 h at 37°C.  For the Vtn-coated 
matrix, DMEM with 10% FCS was added to the bottom chamber and incubated for 4 h at 
37°C.  For the evaluation of G-protein interactions, 50 µg/ml PTX was incubated at 37ºC 
overnight prior to assay.  The cells that were attached to either side of the Transwell 
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membranes were removed, fixed with methanol, stained with 1% Coomassie, and 
destained with acetic acid.  Then absorbance at 506 nm was read using a SpectroMax® 
Plus 384 microplate spectrophotometer (Nguyen, Hussaini et al. 1998). 
 
2.2.23. Cell signaling:  
Cells were seeded with DMEM into a six well plate and incubated at 37ºC with 5% 
CO2 until 80% confluence was reached.  The day before the experiment, cells were 
washed three times with PBS, and the medium was replaced with SF DMEM for 18 h.  
After serum starvation, the medium was replaced with fresh SF DMEM in the presence 
of one of the following: undiluted fetal calf serum, 10 nM tcu-PA, 40 µM PD98059, 10 
µM JNK II inhibitor or a combination of the all of the above.  Cells were then stimulated 
for 5 min at 37°C, followed by quenching by washing three times with ice cold PBS/ 100 
µM NaVO4. Cells were then lysed in freshly made PBS/ 1% Triton X-100/ protease 
cocktail inhibitor (Roche).  Lysates were subjected to BCA protein quantitation for equal 
loading. Samples were analyzed by immunoblotting and antibodies against 
phosphorylated ERK, JNK and p38 (Cell Signaling, San Diego CA) were used for cell 
signaling detection. Goat α-rabbit HRP (1:5000) (JackonImmunoReserch) was used for 
detection. Afterwards, blots were stripped using Pierce Stripping buffer for 30 min at 
37°C.  The samples were then re-analyzed using α-ERK (Zymed), α-JNK or α-p38 (all at 
1:1000) antibodies, after which the standard immunoblotting procedure was performed. 
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2.2.24. Cell Death: 
Cells (2,500 /well) were seeded into a 96 well plate, then treated either with SF 
DMEM, DMEM with 10% FCS, DMEM with 10% FCS and CO2 deprivation or SF 
media and 10 nM TNF-α for 24 h at 37°C.  The day of experiment, the media was 
exchanged with fresh DMEM/ 10% FCS following the addition of CellTiter 96® 
AQueous One Solution Reagent (Promega).  The reactions were incubated for 1.5 h at 
37°C/ 5% CO2.  Cell density was determined using the proliferation assay outlined 
above.  
 
2.2.25. Caspase assay: 
293 cells, wt u-PAR cells and cr-uPAR cells were subjected to SF DMEM or DMEM 
containing 10 nM TNF-α (EMD Bioscience, San Diego CA) for 18 h at 37°C.  Cells 
were lysed using TBS/1% Triton-x 100. Cell lystate (50 μg) was incubated for 4 h at 
37°C with Ac-DEVD-AMC substrate following manufacturer’s recommendations 
(Promega). Detection of caspase 3/7 was performed by reading the reaction for 60 min at 
37°C at an excitation wavelength of 360 nm and emission wavelength of 460 nm.  
 
2.2.26. Apoptosis assay:  
293 cells were seeded onto a 24-well plate and subjected to DMEM (with or without 
serum) or SF DMEM with 10 nM TNF-α and 10 µg/ml CHX for 18 h at 37ºC. Media was 
removed and cells were trypsinized followed by washes with PBS. Cells were then 
incubated with PE-Annexin V, per manufacturers recommendations, for 15 min at 37°C. 
Samples were analyzed by flow cytometry and gated for both alive and dead. 
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2.3. Figures and Tables  
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CHAPTER 3. CHARACTERIZATION OF WILD TYPE U-PAR AND MUTANT 
U-PAR VARIANTS 
3.1. Introduction:  
In this chapter, we report the development and characterization of several u-PAR 
variants with increased resistance to proteolysis by tcu-PA.  u-PAR contains a unique 
linker region between D1 and D2 of its multi-domain structure that is extremely sensitive 
to proteolysis by several proteases, including tcu-PA, Pn and matrix metalloproteases 
(Hoyer-Hansen, Ronne et al. 1992; Hoyer-Hansen, Ploug et al. 1997; Montuori, Rossi et 
al. 1999). The chemotactic epitope 88SRSRY92 is found within this region and is exposed 
in the presence of u-PA by either a conformational change induced upon u-PA binding or 
by cleavage of D1 (Fig. 3.1.1) (Fazioli, Resnati et al. 1997).  The D1 of u-PAR can be 
trans-cleaved by a u-PAR bound tcu-PA at two sites (Arg83 and Arg89). The newly 
generated cleaved form of u-PAR (D2D3) is unable to bind u-PA (Hoyer-Hansen, Ronne 
et al. 1992), internalize u-PA-PAI-1 complexes, or efficiently bind Vtn (Montuori, Rossi 
et al. 1999). Cleavage of u-PAR is important in chemotaxis, cell migration and cell 
signaling, (Fazioli, Resnati et al. 1997; Montuori, Rossi et al. 1999; Montuori, Carriero et 
al. 2002; Mazzieri, D'Alessio et al. 2006) but the precise role of receptor cleavage in the 
regulation of cell-surface proteolysis is not clear.  An extensively mutated u-PAR that 
provides cleavage resistance at all sites in the linker region exhibited increased alternative 
signaling-dependent migration compared to the wild type receptor (Mazzieri, D'Alessio et 
al. 2006).  We hypothesized that u-PA regulates u-PAR by altering its function through 
the conformational states u-PAR can adopt. Heterogeneous glycosylation is an inherent 
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problem in studying u-PAR functions. Thus, we engineered a mutant u-PAR with Arg83 
and Arg89 that confers cleavage resistance by tcu-PA.  
 
3.2. Results:  
3.2.1. Site-directed mutagenesis of u-PAR: Generation of a cleavage resistant 
receptor.  
Cleavage of u-PAR by tcu-PA is thought to shift the functions of u-PAR from a 
proteolytic to a non-proteolytic role. To specifically study the effects of resistance to 
cleave by tcu-PA, all other linker region proteolytic sites were conserved including amino 
acids involved in receptor integrity, functionality of the chemotactic region, and 
maintenance of other protein interactions that contribute to chemotaxis.  Figure 3.2.1, 
details the different combination of residues mutated for these studies.  Alanine, a neutral 
residue, was selected as a major target for substitution in order to retain the overall 
structure of the receptor.  An alternative residue to Arg was a Glu, since this residue has 
an opposite charge, retains its size but prevents tcu-PA cleavage. Additionally, we used 
combinatorial or individual mutations to optimize selection of a good candidate for the 
dissection of u-PAR functions. All mutations were confirmed by DNA sequencing (Fig. 
3.2.2) prior to insertion into pDNA3.1 (+) for transfection into 293 cells.  Wt u-PAR and 
cr-uPAR both expressed intact u-PAR at high levels  The addition of exogenous Pn or 
chymotrypsin led to cleavage and degradation of the u-PAR variants.  When tcu-PA was 
added this was not observed for cr-uPAR, supporting the double point mutational 
selection approach.  Stable clones expressing high levels of u-PAR (similar to that 
observed in cancer cells) were selected.   
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3.2.2. Generating stable-transfected 293 cells expressing the u-PAR variants 
293 cells expresses key proteins that initiate internalization (LRP), signaling (ERK, 
FPRL1, and EGFR), migration, proliferation and apoptosis, but does not express u-PAR 
or u-PA (Jo, Takimoto et al. 2009). The 293 cell line was used to identify functional 
abnormalities in the Pg activation system, and was characterized in the absence of u-PAR 
and in the presence of transfected intact full-length u-PAR or cleaved u-PAR.  Wt u-PAR 
and the mutant u-PAR variants were stably transfected into 293 cells and selectively 
treated with 400 µg/ml of G418 for the incorporation of the human u-PAR pcDNA3.1(+) 
plasmid.  Protein expression levels were evaluated following a double round of colony 
selection for all mutants by immunoblotting, then select representatives of u-PAR 
variants were chosen. 
As expected, lysates from non-transfected 293 cells did not express u-PAR (Fig. 3.2.3 
A). In cells expressing wt u-PAR and cr-uPAR, a band at approximately 55 kD represents 
the intact receptor.  The additional band observed at approximately 40 kD in these two u-
PAR variants may represent an underglycosylated or partially degraded u-PAR.  Lysate 
from PMA-stimulated U937 cells were used as a positive control to delineate the 
approximate size of intact receptor (Fig. 3.2.3A).  Stimulation with PMA increases u-
PAR expression and glycosylation, resulting in a heterogeneous population of u-PAR. 
This increase in glycosylation, described previously, is most likely the explanation for the 
appearance of the PMA-stimulated U937 cell associated u-PAR at a higher molecular 
weight than 293 cell associated u-PAR (Behrendt, Ronne et al. 1990).  In Figure 3.2.3 B, 
the u-PAR R83E/R89E lane contains a minor band for the intact form, a major band 
representing the cleaved form, and a third major band of lower molecular weight.  The 
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latter band likely represents a degradation product that formed due to cleavage by MMP-
9, which is known to be expressed in 293 cells and has been shown to cleave at residue 
86.  The u-PAR mutant R83E/R89A however, shows a band representing intact u-PAR and 
two lower bands: one of size similar to the cleaved form and the other similar to that 
observed in the R83E/R89E u-PAR mutant.  These combinational u-PAR variants 
(R83E/R89E and R83A/R89E) did not express well in 293 cells.  Whereas the single mutants 
expressed a significant amount of intact u-PAR, with a smaller additional form consistent 
with the cleaved form of u-PAR (Fig. 3.2.3 C and D).  This additional band is likely a 
cleaved fragment of u-PAR that is more pronounced under conditions of high protein 
expression.  Expression of R83E/R89E and R83E/R89A u-PAR mutants lead to a significant 
loss of adherent properties and were not used further in our studies.  The R83A/R89A 
mutant was utilized for further experiments to ensure stable protein production that would 
not be susceptible to cleavage by MMP-9. This mutant was further designated as 
cleavage resistant u-PAR (cr-uPAR).  
After stable growth was achieved, cr-uPAR was subjected to reverse transcriptase 
PCR confirming the absence of additional unexpected mutations (Fig. 3.2.4).  Non-
transfected 293 cells did not transcribe u-PAR mRNA (lane 6), but the positive control 
for these cells (lane 5) and the 293 cr-uPAR positive control (lane 8) indicated that the 
PCR control, GADPH, was transcribed efficiently.  293 cr-uPAR and positive u-PAR 
cDNA control (lane 9) share a band of identical size.  The cDNA was sequenced to 
confirm the presence of the expected mutations (data not shown).  Flow cytometry was 
then used to determine the relative expression levels (Fig 3.2.5) of cell-surface u-PAR for 
a representative population of both wt u-PAR and cr-uPAR.  293 cells showed a higher 
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affinity for the isotopic control IgG, but the binding of α-human u-PAR polyclonal 
antibody did not show a significant enhancement in intensity, demonstrating a lack of u-
PAR expression on the cell surface.   
 
3.2.3. u-PAR with Arg83 and Arg89 mutated proves to be an effective cleavage 
resistant variant.  
Specificity of cleavage resistance was confirmed by incubation with tcu-PA, another 
proteases known to cleave u-PAR in the linker region (Fig. 3.2.6 A).  Overnight 
incubation of the cells in the absence of exogenous protease failed to produce cleavage 
products (Fig. 3.2.6, lane 2, all panels).  The absence of a cleavage product indicated that 
any cleavage observed in the presence of exogenous proteases would be a result of the 
added enzyme.  Exogenous tcu-PA generated a cleaved form of u-PAR in cells 
expressing wt u-PAR (Fig. 3.2.6 A; left and middle panel), with 70% of the receptor in 
the cleaved form indicating limited proteolysis of u-PAR.  The observed pattern was not 
present in 293 cr-uPAR crude cell lysate (Fig. 3.2.6 A; right panel).  In contrast, cleavage 
products were not observed when 293 cr-uPAR cells were incubated with excess tcu-PA 
for a prolonged time. As expected, the substitution of Ala at Arg83 and Arg89 lead to a u-
PAR that cannot be proteolytically cleaved by tcu-PA.    
Cell variants were then exposed to plasmin (Pn, 250 nM) to determine if u-PAR can 
be cleaved by a known protease that is also part of the Pg activation cascade.  In 3-day 
PMA stimulated U937 cells (Fig. 3.2.6 B, left panel) Pn produced u-PAR cleavage 
products similar to those produced by tcu-PA.  293 wt u-PAR cells (middle panel) did not 
produce a cleavage product in the absence of protease, but in the presence of Pn a marked 
increase of cleavage product resulted.  In 293 cr-uPAR cells (right panel), Pn produced a 
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similar cleavage pattern to that seen in wt u-PAR cells. However, the amount of observed 
cleavage product was significantly decreased, suggesting that there may be multiple 
cleavage sites in u-PAR.  The cleavage profile was continued by using chymotrypsin. 
Both wt u-PAR (left panel) and cr-uPAR (right panel) were sensitive to limited and 
concentration-dependent proteolysis by chymotrypsin (Fig. 3.2.6 C).  Lanes 2 and 3 
contained bands representing intact u-PAR in both wt u-PAR and cr-uPAR panels.  There 
was a decrease of the detected band that can be attributed to epitope loss by cleavage at 
secondary sites. However, a decrease in chymotrypsin concentration, as see in lanes 5 and 
6 for both u-PAR variants, recovers the epitope loss of the cleaved product (Fig. 3.2.6 C).  
These experiments indicate that both wt u-PAR and cr-uPAR are susceptible to cleavage 
by proteases targeting residues in the linker region but not the two mutated Arg residues.  
Dano et al., reported that tcu-PA preferentially cleaves at residue 83, and that cleavage at 
residue 89 occurs to a lesser degree (Sidenius, Sier et al. 2000).  Proteolytic digestion of 
single point mutants, R83A or R89A was evaluated to determine if tcu-PA cleavage 
resistance requires substitution at both Arg sites. Figure 3.2.7, demonstrates intact u-PAR 
with R89A and R83A, lanes 1 and 4 respectively.  In the presence of tcu-PA, the cleaved 
form of u-PAR was produced for the single mutants: R89A (lane 2) and R83A (lane 5).  
Full cleavage was not observed potentially due to incomplete digestion and time of 
exposure. 
Both single point mutants were then subjected to limited proteolysis with 
chymotrypsin (10 nM).  Incubation of 293 u-PAR R89A cells with chymotrypsin (lane 3) 
resulted in <50% cleavage, while incubation with cells expressing R83A resulted in 70-
80% cleavage of the intact receptor. These results suggest that the two single mutation 
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sites may be different with respect to either conformation or the exposure of the linker 
region.   
3.2.4. The cleavage resistant receptor has high affinity interactions with its 
ligands, and is over-expressed in 293 cells.  
To compare the behavior of a mutant cell-surface molecule to its wild type 
counterpart, the binding-affinity for the cognate ligand needs to be similar.  Thus, the 
binding affinities for 293 wt u-PAR and 293 cr-uPAR for an inactive form of u-PA, 
CMK-uPA were evaluated (Fig. 3.2.8). Triplicate of clones for each variant demonstrated 
differing expression levels by immunoblotting.  Due to a tendency for over-expression, 
adherent cells were titrated to identify optimal saturation conditions (data not shown and 
Fig. 3.2.8).  The cell titration identified the optimal cell number of 50,000 cells per well.  
This cell number was used to achieve receptor saturation.  The dissociation constants 
obtained (1.1 nM to 1.5 nM) for three independent cell clones expressing either wt u-
PAR or cr-uPAR (Fig. 3.2.8 A and Table IV) were similar to values observed by other 
groups (Stoppelli, Corti et al. 1985; Plow, Freaney et al. 1986; Estreicher, Wohlwend et 
al. 1989; Beaufort, Leduc et al. 2004). To determine ligand specificity, we exposed the 
non-transfected 293 cells to both CMK-uPA and radiolabeled CMK-uPA and observed 
no specific binding at the ranges studied (Fig. 3.2.8 A).  Comparison of receptor number 
indicated that wt u-PAR expression levels (0.68 - 2.2 x106 receptors /cell) (Table IV, left 
panel) were lower than cr-uPAR expression levels (1.5 - 5.5 x106 receptors / cell) 
(Fig.3.2.8 A and Table IV, right panel).  Immunoblotting of wt u-PAR and cr-uPAR 
confirmed the presence of a single intact protein, which was consistent with expression 
levels determined from the binding assays (Fig. 3.2.8 B). The similarity in binding 
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affinity between wt u-PAR and cr-uPAR demonstrated that cr-uPAR has a conformation 
similar to wt u-PAR, and that cr-uPAR has adequate post-translational modifications 
(glycosylation) to have a high affinity for u-PA. 
 
3.2.5. Binding of tcu-PA to the u-PAR variants promotes plasminogen 
activation.  
cr-uPAR has high affinity binding to u-PA (Table IV). In order to effectively use cr-
uPAR, we questioned if it retained the ability to initiate the Pg activation cascade.  The 
data presented previously demonstrated that cr-uPAR is able to bind u-PA with similar 
affinity to wt u-PAR.  Next, we compared Pg activation between 293 cr-uPAR relative 
and 293 wt u-PAR.  Unoccupied u-PAR was blocked with CMK-uPA, showing a 
significant decrease in Pg activation when supplementary tcu-PA was added, resembling 
the pattern observed with 293 cells incubated with tcu-PA (Fig. 3.2.9 A). 293 cr-uPAR 
cells and 293 wt u-PAR cells similarly initiated the cascade in the absence of CMK-uPA.  
The slight increase in Pn generation by wt u-PAR is likely a function of the higher level 
of expression of cell surface receptors. 
The ability of the single point mutants, R83A and R89A, to initiate the Pg activation 
cascade was tested since the single point mutations should not impact Pg activation.  
Plasmin generation by the u-PAR R83A mutant was similar to that of wt u-PAR and cr-
uPAR.  The individual clones were compared with regard to expression levels and Pn 
generation to discriminate between an effect due to the mutation and an effect of the 
individual clone’s level of expression with clone 53 demonstrating slightly more Pn 
generation, which was attributed to its higher expression level identified by 
immunoblotting (Fig. 3.2.6 and 3.2.10).  Plasmin generation by the R89A clones was also 
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similar to wt u-PAR and cr-uPAR with clone 43 demonstrating increased Pn generation 
that was associated with high expression levels, while clone 14 generated lower amounts 
of Pn in association with low expression levels (Fig. 3.2.10 and 3.2.6).      
3.2.6. Specificity of u-PAR based plasminogen activation 
Previous research coupled with results shown in section 3.2.3, shows that wt u-PAR 
but not cr-uPAR can be cleaved by tcu-PA, decreasing the amount of available intact 
receptors that can bind tcu-PA.  The availability of intact receptor versus cleaved receptor 
can be observed in experiments where noticeable amounts of cleaved wt u-PAR are seen 
in the absence of extrinsically added protease, when compared to cr-uPAR (Fig. 3.2.6).  
Cleaved u-PAR generated by limited proteolysis with tcu-PA or chymotrypsin was used 
to ascertain the effect of D1 removal from cell-surface u-PAR.  Cleavage of wt u-PAR 
with either tcu-PA or chymotrypsin prior to binding tcu-PA (Fig. 3.2.11) resulted in a 
50% decrease in Pn generation, similar to reports by other investigators (Hoyer-Hansen, 
Ronne et al. 1992; Hoyer-Hansen, Behrendt et al. 1997).  Exposure of cr-uPAR to tcu-PA 
resulted in a 25% increase in Pn generation, which was attributable to the available cr-
uPAR sites.  Exposure of cr-uPAR to chymotrypsin resulted in a 50% decrease in Pn 
generation (Fig. 3.2.11).  Cr-uPAR was expected to have equal or more tcu-PA-mediated 
Pn generation, but similar or less chymotrypsin-mediated Pn generation due to resistance 
to D1 cleavage. 
 
3.2.7. cr-uPAR has a decreased rate of fibrin clot lysis than its wt u-PAR 
counterpart.  
Non-transfected, 293 wt u-PAR, and 293 cr-uPAR cells were evaluated for the ability 
to degrade fibrin clots.  As a control, evaluation of acid washed 3-day PMA stimulated 
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U937 cells indicated that cells were not able to degrade fibrin, unless scu-PA was added 
(3.2.12 A).  Under similar buffering conditions as U937 cells, 293 cells were able to 
degrade fibrin clot (data not shown), likely due to endogenous production of MMP-9 
which has fibrinolytic activity.  To limit cell-mediated fibrin degradation, EDTA, which 
is known to inhibit MMPs, was incorporated into the buffer. In the presence of EDTA, 
non-transfected 293 cells did not degrade fibrin clots, even with exogenous scu-PA added 
(Fig. 3.2.12 B).  In comparison, 293 wt u-PAR cells were able to cause 50% degradation 
in the presence of scu-PA.  Unexpectedly, 293 cr-uPAR cells delayed degradation at 20 
min, with 50% degradation at 90 min (Fig. 3.2.12 C). Since both u-PAR variants bound 
u-PA with similar affinities we stipulate that a downstream effect or mechanism is 
altering fibrin clot lysis. 
 
3.3. Discussion: 
Prior to this study, the cleavage resistant u-PAR mutant available did not retained 
interactions with both u-PA and Vtn. Indeed, previously published mutational analysis 
studies have failed to provide useful insights into the differences between intact u-PAR 
and cleaved u-PAR.  One study using a cleavage resistant u-PAR, termed hcr-uPAR, 
indicated a possible impact on signaling pathways (Mazzieri, D'Alessio et al. 2006).  
However, hcr-uPAR had the linker region extensively mutated altering all the proteolytic 
sites, including two of the five residues (R89 and R91) in the chemotactic epitope.  Studies 
performed using Ala scanning were used as means to identify protein interactions 
between u-PAR and Vtn or integrins and they noted that mutation to R91 of the linker 
region interferes with Vtn interactions (Madsen, Ferraris et al. 2007).  Such a mutation 
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causes difficultly in isolating functional differences, since a Vtn binding site is also 
abolished.   
tcu-PA trans-digests u-PAR, dissociating D1, and thus rendering it unable to bind u-
PA. The interaction between u-PA and u-PAR is complementary, since cleavage cannot 
occur without binding.  During the interaction between the ligand and receptor, both 
active site-dependent events and non-active site dependent occur.  This is also true when 
generating a cleaved u-PAR changing the receptor from a proteolytic to non-proteolytic 
function.  Limiting our mutations to the two Arg cleavage sites allowed for the generation 
of a tcu-PA cleavage-resistant receptor that retained significant function and preserved 
other known protein interactions that is important for chemotactic effectiveness. 
In cancer studies, there is strong evidence of a role for soluble and cleaved forms of 
u-PAR, indicating a potential important role for u-PAR cleavage (Hoyer-Hansen review).  
However, there is little direct evidence implicating cleaved u-PAR in these events, since 
most of these effects are inducible by ligand-bound u-PAR (Ragno review 09).  This 
leads to questions whether cleaved u-PAR is a regulatory step for the variety of functions. 
The only direct evidence of a specific role for cleaved u-PAR is an involvement in the 
differentiation of myofibroblast to fibroblast (Brenstein, 2009). However, these 
experiments were conducted using hcr-uPAR, as mentioned above, which also lacks Vtn 
binding.   
Cells expressing the u-PAR variants R83E/R89A or R83E/R89A lost their adhesive 
properties or were prone to cell death, making the collection and isolation of these cell 
lines challenging.  The effects observed with these mutants may be a result of an alternate 
conformation. Charge substitution in the linker region by exchanging the Arg to a Gln 
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could potentially disrupt the known multiple protein interactions. Thus, substitution of 
Arg to Ala may be key for these studies, since cr-uPAR retains the wt u-PAR functions 
and does not disrupt protein-protein interactions.   
The cr-uPAR clones expressed similar high levels of u-PAR, and were comparable to 
the expression levels observed in cancer cells. The cleavage profile observed with the 
single point mutations supports the use of the double point mutant to confer resistance to 
tcu-PA cleavage while maintaining other proteolytic sites.  For future experiments, single 
point mutants can aid in the dissection of residues important for specific functions. 
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CHAPTER 4. CR-UPAR IS IN A CONFORMATION THAT IS 
PREDOMINANTLY U-PA INDEPENDENT  
 
4.1. Introduction:  
The dissection of u-PAR activation mechanisms and their downstream effects is of 
great medical interest, since this receptor has been implicated in both physiological and 
pathophysiological processes, and has emerged as a potential therapeutic target in 
neoplasia.  Emerging evidence suggests that conformation is an important aspect of u-
PAR function. Indeed, u-PAR exists in at least three functionally distinct states: 1) full-
length ligand-free (its latent or inactive state); 2) full-length with u-PA bound (its 
activated state); and 3) cleaved receptor (which no longer binds u-PA, but is active due to 
the proteolytically-exposed chemotactic peptide) (Ploug and Ellis 1994; Ploug, Ellis et al. 
1994; Fazioli, Resnati et al. 1997; Huai, Mazar et al. 2006; Yuan and Huang 2007; Huai, 
Zhou et al. 2008). u-PAR crystal structures support conformational flexibility, with 
multiple receptor conformations depending on the ligand, such the antagonist ATF of u-
PA, and the SMB domain of Vtn (Llinas, Le Du et al. 2005; Barinka, Parry et al. 2006; 
Huai, Mazar et al. 2006; Huai, Zhou et al. 2008). Functional studies of different receptor 
states has been complicated by the fact that some of the functions of u-PA-bound u-PAR 
and the cleaved receptor overlap (Resnati, Guttinger et al. 1996; Nguyen, Hussaini et al. 
1998; Montuori, Carriero et al. 2002).  Also, u-PAR is a substrate for its own cognate 
ligand, u-PA (Hoyer-Hansen, Ronne et al. 1992; Hoyer-Hansen, Ploug et al. 1997; 
Hoyer-Hansen, Pessara et al. 2001).  Thus, the presentation of u-PA to u-PAR leads to 
activation of the receptor by two overlapping mechanisms that are difficult to separate.  
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u-PAR contains a unique linker region between D1 and D2 of its multi-domain (D1-
D3) structure that is exposed in the presence of u-PA either by conformational change or 
cleavage of D1 (Fazioli, Resnati et al. 1997; Huai, Mazar et al. 2006; Huai, Zhou et al. 
2008).  Bound tcu-PA cleaves D1 of u-PAR at two sites (R83 and R89), generating the 
cleaved form of u-PAR (D2D3) that is unable to bind u-PA (Hoyer-Hansen, Ronne et al. 
1992), internalize u-PA-PAI-1 complexes, or efficiently bind Vtn and other matrix 
constituents (Montuori, Rossi et al. 1999).  Cleavage of u-PAR is important in 
chemotaxis, cell migration and cell signaling, but the role of receptor cleavage in 
regulating several other cell-associated processes is not well understood (Fazioli, Resnati 
et al. 1997; Montuori, Rossi et al. 1999; Montuori, Carriero et al. 2002; Mazzieri, 
D'Alessio et al. 2006).  This suggests that a ligand that strengthens the interaction 
between u-PAR and Vtn or integrins also has the potential to modulate the roles of u-
PAR in chemotaxis, cell migration, and cell signaling. 
In this section we demonstrate that 293 cr-uPAR cells exhibit normal promotion of 
cell-surface Pg activation. Clearance of u-PA-PAI-1 complexes, receptor recycling, and 
cell migration were enhanced in cr-uPAR expressing cells compared to cells expressing 
wt u-PAR.  We also observed that cr-uPAR closely associates with LRP with higher 
affinity than wt u-PAR, regardless of whether u-PAR is unoccupied or bound to u-PA-
PAI-1 complexes, resembling more the ligand-bound form than the unliganded form. 
Enhanced internalization of cr-uPAR might be related to an increase in pre-assembly of 
unoccupied u-PAR with LRP.  We hypothesized that cr-uPAR retains some abilities 
associated with conformationally active u-PAR. Whether cr-uPAR confers advantages to 
cells (similar to heavily glycosylated cleavage-resistant u-PAR in cancer cells) awaits 
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further study (Ragno, Montuori et al. 1998; Montuori, Rossi et al. 1999; Montuori, 
Carriero et al. 2002).    
 
4.2. Results: 
4.2.1. Cell surface regulation of scu-PA and tcu-PA 
PAI-1 plays a central role in inhibiting Pg activation by reversibly inhibiting scu-PA 
and irreversibly inhibiting tcu-PA, which is necessary for proper down-regulation of 
extracellular proteolysis.  When we evaluated the ability of PAI-1 to access tcu-PA bound 
to cell-surface u-PAR, we found that cell-surface bound tcu-PA was efficiently 
inactivated by PAI-1 on both wt u-PAR cells and cr-uPAR cells (Fig. 4.2.1). Intriguingly, 
cr-uPAR cells had higher activity than wt u-PAR cells following treatment with PAI-1 
(20% versus 5%, respectively). Cells expressing cr-uPAR may have mostly intact 
receptors on the cell surface, while cells expressing wt u-PAR may have more tcu-PA 
mediated cleavage. Since u-PA-PAI-1 complex formation is irreversible, we detected 
very little Pn generating activity from pre-formed complexes bound to the cell surface 
(Fig. 4.2.1 A). These data suggest that initiation and inhibition of Pg activation occur 
similarly on wt u-PAR cells and cr-uPAR cells.   
Similar experiments using scu-PA rather than tcu-PA yielded unexpected results (Fig. 
4.2.1 B).  Because the scu-PA:PAI-1 interaction is reversible, we expected that Pn would 
be generated.  Inhibition of scu-PA by PAI-1 with cells expressing wt u-PAR resulted in 
a 70% increase in Pn activity.  Interestingly, with cells expressing cr-uPAR, there was 
only 25 - 30% activity. scu-PA:PAI-1 pre-complexes were then generated and allowed to 
bind to the u-PAR variants.  For wt u-PAR we observed an 85% increase in proteolytic 
activity.  On the other hand, cr-uPAR cells did not yield a significant change in activity.  
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Inhibition studies of u-PAR bound scu-PA or the pre-complexed scu-PA:PAI-1 yielded 
similar results for cr-uPAR. These results are consistent with the observations found in 
the fibrinolytic system (shown in chapter 3) and leads us to speculate a possible 
difference between scu-PA and tcu-PA.  
 
4.2.2. Cells expressing cr-uPAR internalize u-PA-PAI-1 complexes more 
rapidly than those cells expressing wt u-PAR. 
Internalization and clearance of u-PA-PAI-1 complexes are vital for the down-
regulation of the Pg system.  Inhibited u-PA bound to PAI-1 forms a hetero-trimeric 
complex with u-PAR that binds to the endocytic receptor, LRP.  The resulting hetero-
tetramer is internalized, u-PA-PAI-1 complexes are degraded, and LRP is recycled to the 
cell surface. In several cell types, levels of LRP expression are the limiting factor in the 
internalization and recycling rate of u-PAR (Li, Kuo et al. 1994; Nykjaer, Kjoller et al. 
1994; Henic, Sixt et al. 2006).  Because u-PAR is essential for the rapid endocytosis of u-
PA-PAI-1 complexes, we examined the effect of the u-PAR mutations on this receptor 
function.   
Upon pulse-labeling a pool of cell-surface receptors with biotin and addition of u-PA-
PAI-1 complex, we detected u-PAR in the cytoplasmic fraction. Consistent with previous 
reports, cytoplasmic wt u-PAR increased in a gradual time-dependent manner to a 
maximum internalized amount at 13 min, followed by a gradual decline (Fig. 4.2.2 A) 
(Cortese, Sahores et al. 2008).  In contrast, cr-uPAR bound to u-PA-PAI-1 complex was 
internalized with an initial peak that was detected at the first studied time point, followed 
by a secondary peak which resembles the endocytic profile of wt u-PAR, thus showing a 
shift in time frame for complex recycling (Fig. 4.2.2 B). RAP binding to LRP inhibits 
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endocytosis mediated by this cell-surface receptor (Griffith, Breitkreutz et al.). Figure 
4.2.2 shows that RAP inhibits LRP-mediated endocytosis of u-PAR:u-PA-PAI-1 
complexes to 10% of peak values seen in the absence of RAP. Thus, although a similar 
process may mediate the internalization of both types of receptors, cr-uPAR undergoes 
this process at a much faster rate compared to wt u-PAR. We evaluated the 
internalization of wt u-PAR and cr-uPAR in the absence of u-PA-PAI-1 complexes, to 
identify if the initial burst of cr-uPAR endocytosis was due to a mutant-specific response 
toward u-PA-PAI-1 exposure (Fig. 4.2.2 B). We found that cr-uPAR was rapidly 
internalized at 3 min in a manner similar to that seen in the presence of u-PA-PAI-1 
complex (Fig. 4.2.2 B). A secondary internalization peak was seen at 33 min, consistent 
with a basal endocytosis cycle of about 30 minutes. While wt u-PAR internalization 
remained under 2% of total labeled receptor, internalization of cr-uPAR reached twice 
that level (Fig. 4.2.2 A). These data suggest that the initial rapid cr-uPAR internalization 
event can occur independently of the binding of u-PA-PAI-1 complexes. 
To determine whether internalization of cr-uPAR is LRP-mediated, RAP was added 
to prevent LRP-mediated internalization. The initial burst of internalization was not 
observed for cr-uPAR internalization, and overall internalization was markedly inhibited. 
A similar findings was observed for wt u-PAR.  These results suggest that endocytosis 
and clearance of the u-PA-PAI-1 complexes is primarily LRP-dependent. To rule out the 
possibility that biotinylation of u-PAR affected its internalization profile, a similar 
experiment was performed using biotinylated-PAI-114-1B in complex with tcu-PA (Fig. 
4.2.4).  The results generated a similar endocytosis profile as those observed using 
biotinylated u-PAR.  Both wt u-PAR and cr-uPAR cells exhibited similar peak 
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internalization (at 18 min), and an initial burst occurred with cr-uPAR (Figure 4.2.2 A).  
Furthermore, lower molecular weight biotin-positive species appeared in conjunction 
with the decrease in cytoplasmic biotinylated u-PA-PAI-1 complex, consistent with 
lysosomal degradation of the endocytosed complex (data not shown).  The presence of 
RAP dramatically diminished u-PA-PAI-1 complex internalization, indicating 
involvement of LRP-mediated endocytosis. 
 
4.2.3. cr-uPAR recycling is increased following internalization of u-PAR:u-PA-
PAI-1 complexes. 
u-PAR and LRP internalization is followed by recycling of these receptors to the cell 
surface and their spatial redistribution (Nykjaer, Conese et al. 1997).  Having observed an 
initial rapid internalization of cr-uPAR, we determined whether the endocytosis of u-PA-
PAI-1-bound cr-uPAR is followed by recycling/resurfacing of unliganded receptor.  
Receptor recycling was studied by saturating cell-surface u-PAR with u-PA-PAI-1 
complexes, inducing internalization, and detecting resurfaced unoccupied u-PAR via 
binding of active tcu-PA in a Pg activation assay.  Figure 4.2.5 shows that cells 
expressing cr-uPAR recycle the receptor faster than their wild-type receptor-expressing 
counterparts. Approximately half of internalized cr-uPAR had reappeared on the cell-
surface 15 min after the induction of endocytosis, while internalized wt u-PAR required 
nearly twice the time (30 min) to reach a similar level of resurfacing.  For the entire 
course of the experiments, synthesis of new receptor was prevented by the addition of 
CHX.  Exposure of cells to RAP before addition of u-PA-PAI-1 complexes resulted in 
marked inhibition of receptor resurfacing, suggesting that LRP-mediated endocytosis is 
required for the appearance of unoccupied receptor on the cell surface and that 
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unoccupied receptor does not appear via simple dissociation of the initially formed u-
PAR:u-PA-PAI-1 complex. 
 
4.2.4. cr-uPAR binds LRP in the absence of u-PA-PAI-1 complex.   
LRP associates with u-PAR bound u-PA-PAI-1 complexes (Andreasen, Sottrup-
Jensen et al. 1994).  This interaction is primarily between the u-PA-PAI-1 complex and 
LRP, though a direct u-PAR:LRP interaction may play a minor role (Czekay, Kuemmel 
et al. 2001).  Since cr-uPAR has an altered LRP-mediated internalization profile which 
occurs even in the absence of u-PA-PAI-1 complex, we determined whether cr-uPAR and 
LRP are closely associated by co-immunoprecipitaion of u-PAR with a monoclonal α-
LRP antibody, 11H4.  In Figure 4.2.6 A and C, a trace amount of wt u-PAR was detected 
using 11H4 in the absence of u-PA-PAI-1 complex.  In the presence of the complex, the 
amount of immunoprecipitated wt u-PAR was enhanced, an effect that was completely 
blocked by RAP (Fig. 4.2.6 A).  In contrast, cr-uPAR alone co-immunoprecipitated with 
LRP, an association that was further enhanced by the addition of u-PA-PAI-1 complex 
(Fig. 4.2.6 B-D).  Indeed, the amount of cr-uPAR precipitated with 11H4 in the absence 
of tcu-PAI-1 complex was comparable to that of wt u-PAR in the presence of the 
complex.   
To disrupt the association of unliganded cr-uPAR and LRP, we selected molecules 
that bind specifically to u-PAR or LRP.  The SMB domain of Vtn directly interacts with 
u-PAR in the linker region N-terminal to our mutated sites, while RAP prevents binding 
of several ligands to LRP.  Figure 4.2.6 D shows that both SMB and RAP inhibited the 
co-immunoprecipitation of cr-uPAR by 11H4.  Disruption of the cr-uPAR:LRP 
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interaction suggests that the receptors can directly interact or may be bridged by other 
unidentified molecules that specifically bind both receptors. 
These studies were continued using peptides that target the linker region of u-PAR, 
blocking the interaction of the receptor with other binding partners.  Peptides 7 and 25, 
were originally discovered using the epitopes found in u-PAR:ATF complexes.  Peptide  
7 is derived from the SMB region in Vtn, (Fong, Doyle et al. 2002) and directly binds to 
u-PAR in the linker region (Gardsvoll and Ploug 2007). Peptide 25 blocks the u-PAR-
integrin β1 interaction (Wei, Lukashev et al. 1996).  A peptide derived from prothrombin 
(Pt peptide) was also used to demonstrate specificity of the peptides 7 and 25.  In the 
absence of u-PA-PAI-1 complexes, peptides 7 and 25 caused a marked decrease in 
LRP:u-PAR interaction, while Pt peptide had no effect (Fig. 4.2.7) (Wei, Eble et al. 2001; 
Wei, Czekay et al. 2005).  As expected, both peptides 7 and 25 partially disrupted the 
interaction between cr-uPAR with LRP in the presence of u-PA-PAI-1 complexes.  These 
results indicate that cr-uPAR binding to LRP is a direct interaction, rather than merely a 
function of co-localization in discrete membrane domains such as clathrin-coated pits.  
 
4.2.5. Chymotrypsin cleaves cr-uPAR at a different rate than wt u-PAR. 
Previous studies have demonstrated that u-PA bound to u-PAR exposes the 
chemotactic epitope situated between residues 88 - 92 in the linker region (Llinas, Le Du 
et al. 2005; Barinka, Parry et al. 2006; Huai, Mazar et al. 2006; Huai, Zhou et al. 2008).  
X-ray crystallographic evidence suggests this u-PA-dependent conformational change in 
the receptor involves the rotation of Tyr87 away from the bulk solvent, thus decreasing its 
availability as the P1 residue for the chymotrypsin active site (Barinka, Parry et al. 2006; 
Huai, Zhou et al. 2008).  Cells expressing wt u-PAR and cr-uPAR were exposed to 
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chymotrypsin in the presence or absence of the inhibited u-PA, CMK-uPA, to determine 
whether the linker region of cr-uPAR is conformationally altered compared to that of wt 
u-PAR (Fig. 4.2.8). Wt u-PAR alone was rapidly cleaved by 100 nM chymotrypsin, with 
most of the receptor converted to the D2D3 form within 1 min, and no detectable intact 
receptor remaining after approximately 5 min.  The presence of CMK-uPA only slightly 
reduced the cleavage of wt u-PAR.  In contrast, cr-uPAR cleavage by chymotrypsin was 
delayed, with intact receptor detectable until about 20 min into the reaction. CMK-uPA 
further delayed the cleavage of cr-uPAR by chymotrypsin, with roughly half of the 
receptor still being intact by the final time point (30 min). Thus, the addition of CMK-
uPA to cr-uPAR expressing cells reduced chymotrypsin-associated receptor cleavage to a 
much greater extent than seen in similarly treated wt u-PAR expressing cells.  Previous 
work demonstrated that u-PA binds with high affinity to both u-PAR (Table I), indicating 
that the differential protection of CMK-uPA against chymotrypsin is not a function of 
dissimilar u-PA-binding. These experiments suggest that there is a significant 
conformational difference between the linker regions of wt u-PAR and cr-uPAR that may 
correlate with different degrees of receptor behavior, such as receptor internalization and 
LRP-association. 
 
4.3. Discussion:  
Models for the function of u-PAR are complex and involve roles for the unoccupied 
receptor, u-PA-bound receptor, and u-PA-cleaved receptor.  The exact consequences of 
each of these states may differ depending on the other receptors expressed on the same 
cell, the composition of the cellular environment, and the type of matrix in contact with 
the cell.  Further confounding matters is the fact that the primary physiologic ligand of u-
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PAR, u-PA, is also a potent source of cleaved receptor (Hoyer-Hansen, Ploug et al. 1997; 
Hoyer-Hansen, Pessara et al. 2001). In a simplified model, u-PA-binding is proposed to 
enhance the association of u-PAR with Vtn (Hoyer-Hansen, Behrendt et al. 1997) and 
integrins (Chapman and Wei 2001). While u-PA-dependent release of D1 abolishes 
affinity for Vtn and integrins, and promotes binding to and signaling via G-protein 
coupled receptors such as FPRL-1 (Resnati, Pallavicini et al. 2002).  These different 
interactions lead to changes in cellular migration, proliferation, and adhesion via 
simultaneous down-regulation of some signaling pathways (eg. those involving integrins) 
and upregulation of others (eg. those involving GPCRs) (Blasi and Carmeliet 2002).  In a 
mixed population of receptors, however, it is difficult to delineate the specific 
contributions of u-PAR states. 
Previous work attempted to address this issue using an uncleavable u-PAR variant, 
hcr-uPAR, which contained mutations of cleavage sites in the linker region for u-PA, 
plasmin, MMPs, and chymotrypsin (Liu, Aguirre Ghiso et al. 2002; Mazzieri, D'Alessio 
et al. 2006; Bernstein, Twining et al. 2007).  While wt u-PAR exhibited u-PA-dependent 
ERK activation, hcr-uPAR did not, suggesting that cleaved u-PAR accesses alternate 
signaling pathways from intact u-PAR (Mazzieri, D'Alessio et al. 2006).  Disruption of 
fibroblast to myofibroblast differentiation by hcr-uPAR further suggested that u-PAR 
cleavage is necessary for differentiation (Bernstein, Twining et al. 2007). However, since 
two of five residues in the chemotactic epitope (Arg89 and Arg91) were altered in hcr-
uPAR, including a residue essential to vitronectin-binding (Arg91), it is unclear whether 
the functional differences observed between intact wt u-PAR and hcr-uPAR are solely 
related to cleavability (Madsen 2006; Gardsvoll 2007; Huai 2008). 
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cr-uPAR, is resistant to cleavage by u-PA but alters only one residue, Arg89, in the 
chemotactic epitope and preserves the ability of the cells expressing the receptor to 
interact with a Vtn-rich matrix.  This mutant receptor binds to u-PA and promotes Pg 
activation indistinguishably from wt u-PAR, implying that cr-uPAR is properly folded 
and oriented on the cell surface, allowing u-PA and Pg to interact.  There also appears to 
be a close association between cr-uPAR and LRP. This result was unexpected given a 
tight interaction of these two receptors requires was thought to require the bridging effect 
of the u-PA-PAI-1 complex. Furthermore, the secondary profile of LRP-mediated 
internalization  for cr-uPAR was the same as cells expressing wt u-PAR.  
Moreover, unliganded cr-uPAR is constitutively endocytosed in an LRP-dependent 
manner, cr-uPAR and LRP can be co-precipitated from cell lysate, and this co-
precipitation can be specifically blocked by RAP and SMB.  These data may be 
explained by direct binding between cr-uPAR and LRP, by the two molecules indirectly 
co-associating within a larger cell-surface complex, or by the two receptors being co-
localized in the same plasma membrane micro-domains.  The data do not allow for 
discrimination between these possibilities, but the results suggest an intriguing 
implication: that cr-uPAR may represent a receptor variant that is constitutively active in 
the absence of ligand. 
In several functional aspects, free cr-uPAR behaved similarly to liganded wt u-PAR.  
For instance, the peak amount of wt u-PAR endocytosed in the presence of u-PA-PAI-1 
complex was similar to the peak amount of cr-uPAR internalized in the absence of the 
complex.  Also, the amount of cr-uPAR that was precipitated with an α-LRP antibody 
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without u-PA-PAI-1 complex was identical to the amount of wt u-PAR captured in the 
presence of complex. 
Note that while contaminant bovine-derived u-PA (from the serum) may have been 
present, binding of u-PA to human u-PAR is species-specific, so bovine-derive u-PA was 
unlikely to influence the results.  In particular, regions known to mediate this specificity 
do not involve the residues mutated in cr-uPAR, and a residue in human u-PA, Trp30, 
critical to this specificity is not conserved in bovine u-PA (Huai, Mazar et al. 2006).  
Thus, it is highly probable that, in the absence of added exogenous human u-PA, cr-
uPAR was unoccupied. 
The mechanism of this activation may involve local changes in the conformation of 
the linker region and chemotactic epitope, as evidenced by the differential susceptibility 
of wt u-PAR and cr-uPAR to partial proteolysis by chymotrypsin.  This structural change 
may in turn affect the inter-domain relationships in the receptor, subtly altering its global 
conformation.  Crystal structures of u-PAR in complex with various ligands including an 
antagonist peptide, the ATF of u-PA, and SMB, demonstrate just such differences in 
inter-domain distances and inter-domain loop conformations (Llinas, Le Du et al. 2005; 
Barinka, Parry et al. 2006; Huai, Mazar et al. 2006; Huai, Zhou et al. 2008).  Although 
more biophysical characterizations are needed to ascertain whether unliganded cr-uPAR 
is conformationally similar to u-PA-bound wt u-PAR, it is clear that cr-uPAR is a 
functionally activated receptor in the absence of ligand-binding.  The questions of 
whether or not other aspects of receptor function are upregulated in cr-uPAR, and the 
possible impact of this putative activation on cellular behavior, await further study. 
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The precise role of u-PAR cleavage in cancer biology remains elusive. Soluble and 
cell-surface cleaved u-PAR are promising markers in the early detection, prognosis, and 
monitoring of response to treatment of cancers of the prostate, ovary, breast, and bone 
marrow (for a review, see (Rasch, Lund et al. 2008). Since cleaved u-PAR can induce u-
PA independent cell migration via GPCRs, receptor cleavage may promote metastasis 
(Montuori, Carriero et al. 2002).  However, in at least the aggressive cancer, anaplastic 
thyroid carcinoma, u-PAR cleavage is prevented by over-glycosylation (Ragno, Montuori 
et al. 1998).  Less aggressive forms of thyroid carcinoma, as well as benign thyroid 
adenoma, express cleavable receptor. Thus perhaps in thyroid cancers, u-PAR cleavage 
down-regulates invasiveness (Ragno, Montuori et al. 1998).  Cr-uPAR may consequently 
represent an important tool in the dissection of the roles of u-PAR in cancer. Further 
investigation into the constitutive activity of this mutant may shed light on the ligand-
induced conformational activation of the intact wild-type receptor. 
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4.4. Figures and Tables:  
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CHAPTER 5. EFFECTS OF CR-UPAR ON CELL MORPHOLOGY AND 
BIOLOGY  
 
5.1. Introduction  
The expression of u-PA and u-PAR on cancer cells modulate adhesion and migration, 
which in turn can determine metastatic potential, in vitro studies, tumor progression and 
patient survival, in vivo studies. There is increasing evidence linking over-expression of 
u-PA and u-PAR and several cancer cell lines (Plesner, Ralfkiaer et al. 1994; Shetty and 
Idell 1998; Mustjoki, Alitalo et al. 1999).  The expression of cell surface proteins changes 
how a cell interact with its environment, promoting an increase in cellular adhesion, 
migration and cytoskeleton rearrangement. The binding of u-PA to u-PAR induces a 
conformational change in u-PAR which activates the receptor however, u-PA binding is 
dependent on the presence of an intact receptor with a significant decrease in affinity 
when u-PAR is converted to the cleaved form.  The formation of cleaved u-PAR is 
hypothesized to be accompanied with exposure of the chemotactic epitope.  Accordingly, 
the binding of u-PA to u-PAR should promote re-distribution of active u-PA to the 
leading edge of migrating cells promoting proteolysis (Estreicher, Muhlhauser et al. 
1990).  In contrast, u-PA cleavage of cell surface u-PAR can block integrin-dependent 
signaling, altering cytoskeleton rearrangement by reducing signals to actin (Margheri, 
Manetti et al. 2006).     
Recently, u-PAR studies have focused on protein interactions, which are dependent 
on the conformation of u-PAR.  u-PAR interacts with many cell surface proteins 
including Vtn, integrins, GPCR and EGFR, with many of these interactions requiring an 
intact form of u-PAR. Currently the interactions of u-PAR with the aforementioned 
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proteins are hypothesized to promote cellular changes via a multiprotein signaling-
receptor complex (MSRC). The preferential interaction of u-PAR with Vtn and other 
proteins on the extracellular matrix induces cellular adhesion to Vtn. Vtn can activate 
Rac-1, a small GTPase, which can then regulate the downstream pathway involved in 
actin polymerization (Wei, Lukashev et al. 1996; Kjoller and Hall 2001; Ma, Thomas et 
al. 2002).  Additionally, 293 cells expressing the intact form of u-PAR on a cell surface 
directs the interaction from a primarily fibronectin base to a Vtn based attachment (Waltz 
and Chapman 1994; Waltz, Natkin et al. 1997).  This effect is thought to be u-
PAR:integrin mediated, since in the absence of u-PAR the cells adhere via a integrin-
fibronectin interaction.  Our studies demonstrate the dramatic difference in cell 
morphology between cells that express the inactive receptor (wt u-PAR) and a 
constitutively active receptor (cr-uPAR).  Previously, these enhanced morphology 
changes were attributed to the binding of u-PA to u-PAR.  A pronounced morphologic 
change was seen in 293 cr-uPAR cells, consistent with a uPA-bound form of u-PAR.  
However, we do not see a significant difference in Vtn adhesion between the two u-PAR 
variants.  
 
5.2. Results: 
5.2.1. Expression of u-PAR alters the cells by elongating their processes. 
The expression of u-PAR is known to influence changes in morphology.  When u-
PAR is expressed on the cell surface it induces polarization that leads to process 
elongation.  We found that cells expressing cr-uPAR had changes in cell morphology 
once the cells were stably transfected.  The visual difference observed between the 293 
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non-transfected cells and u-PAR expressing cells led us to look at basal changes in the 
cell morphology.  293 cells which either were not transfected or have only the blank 
plasmid, pcDNA3.1(+), transfected had no change from previously reported morphology 
(figure 5.2.1).  The expression of wt u-PAR on the cell surface in all clones selected led 
to a dramatic change in flattening of the cells, conversion to an elongated form, reduction 
of the cell body, an extensive formation of lamellipodia and F-actin cytoskeleton 
rearrangement, also observed by several other researchers. In addition, since the u-PA:u-
PAR interaction is species-specific, the presence of FBS which contains bovine u-PA 
should not affect the study.  When cr-uPAR is expressed on the cell surface, we observed 
a more prominent processes elongation than that of wt u-PAR. Not surprisingly, 
processes elongation scored by three unbiased independent researchers led to unequivocal 
similar assignments of processes. The observed effect here was also clone independent 
(figure 5.2.1 bottom left panel).  However, at least for wt u-PAR, the observed effects 
were expression level dependent since clone 11 expresses twice the amount of clone 4 yet 
had prominent elongated processes similar to that of cr-uPAR.  On the other hand, 
expression of cr-uPAR did not have a significant impact on processes elongation. The 
cell-cell contacts between the cr-uPAR cells had changed in comparison to both 293 cells 
and 293 wt u-PAR cells with a larger population of cells localizes in the same region, 
making contact along the protrusions. Furthermore, some cells had both lamellipodia and 
filopodia.  As mentioned in Chapter 3, we used similar expression levels for both u-PAR 
variants in an effort to prevent the over-expression of u-PAR.  We tested whether the cell 
morphology for the u-PAR variants could be reverted to that of 293 non-transfected cells 
by treating the cells with a D-mannosamine (Fig. 5.2.2). D-mannosamine blocks the 
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generation of a GPI-tail and prevents all GPI-anchored proteins from being transported to 
the cell surface. Both u-PAR expressing cells reverted the morphology of 293 non-
transfected cells, while treatment of 293 non-transfected cells with D-mannosamine 
caused no morphological changes. Neither integrins nor LRP are affected by this 
treatment since, these are transmembrane proteins that lack any GPI modifications. This 
shows that u-PAR expression is potentially responsible for the changes observed.  
      
5.2.2.  Localization of u-PAR to focal adhesion points. 
We next determined the distribution of u-PAR on the cell surface, since investigators 
have reported the receptor spreading evenly along the cell surface.  We noted in the 
previous section that 293 cr-uPAR cells have longer processes, compared to 293 wt u-
PAR cells. Fluorescently tagged CMK-uPA was used to identify how the over-expressed 
receptor is distributed. Fluorescently tagged u-PA was distributed along the cell surface 
extending to the processes elongations. u-PA also localized to the cell-cell attachments 
and focal adhesion sites (Fig. 5.2.3 and 5.2.4).  u-PAR is near the same sites as the actin 
filaments, identified by the addition of rhodamine-labeled phalloidin, which directly 
binds F-actin. We detected no CMK-uPA localization on the cell surface of untransfected 
293 cells.    
293 expressing u-PAR, but not 293 non-transfected, cells had protrusions extending 
from the cell body, accompanied by the formation of lamellipodia. As demonstrated by 
Madsen, our transfected 293 u-PAR cells formed lamellipodia.  In addition, there was an 
increase in the protrusion length of the 293 cr-uPAR that correlated with a narrower cell 
body, resembling highly mobile cells. Indeed, cr-uPAR cells had a small amount of 
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filopodia. These studies suggest that 293 cr-uPAR expressing cells resemble more 
activated u-PAR, rather than the latent counterpart.   
 
5.2.3. u-PAR variants promote enhanced adhesiveness and delay cellular 
dissociation on a Vtn based matrix. 
Since u-PAR directly interacts with Vtn, we determined whether cr-uPAR has an 
altered affinity toward Vtn.  When either wt u-PAR or cr-uPAR were expressed on the 
cell surface, followed by harvesting of cells onto Vtn coated plates, we saw a similar 
increase in adhesion for both receptors, as previously noted for u-PAR (Fig. 5.2.5 A). 
This effect is not entirely surprising, since the cells were non-enzymatically dissociated 
and had the u-PAR variants on the cell surface. However, this method cannot discern 
between latent u-PAR and the u-PA bound active form. When the same experiment was 
performed using FCS we detected the same increase in adhesion as with Vtn. Thus our 
cr-uPAR expressing cells have an increased affinity toward Vtn, promoting adhesion, 
since FCS also contains other matrix proteins which can be utilized by 293 cells to 
adhere, i.e. integrin-mediated fibronectin adhesion.  
We determined whether cell anchorage was altered when cells expressed u-PAR, 
since cell surface expression of u-PAR can shift the binding from integrin-based binding 
to Vtn-based binding. A buffering system that does not have proteases present but mainly 
EDTA allows us to distinguish binding that is primarily integrin dependent versus Vtn 
dependent matrices. The expression of u-PAR on the cell surface made the cells less 
amenable to dissociation (Fig. 5.2.5 B).  However, cells not expressing u-PAR on the cell 
surface were prone to faster dissociation. This is mainly attributed to integrins being 
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unable to associate with a fibronectin matrix, since they are calcium-dependent. These 
dissociation studies confirm an increase in adhesion that is Vtn dependent. A key point is 
cells overexpress the receptor, mimicking the events found in cancer cells.  We suggest 
that over-expression of cr-uPAR may overcome the need for u-PA dependent activation 
of the receptor.  
 
5.3. Discussion 
Expression of u-PAR induces morphologic changes and enhanced adhesion in cells, 
as previously reported. The interaction of u-PAR with Vtn directly affects the adhesion 
characteristics of cells, at least in our system. Strong adhesion to a cell matrix, such as 
Vtn, can promote cell growth and cell differentiation, a trait that cancer cells assume after 
they have migrated to a new environment. Integrins are another set of molecules that 
interacts with u-PAR, although recently there have been some conflicting studies which 
question if this interaction is direct or indirect via lateral interplay. The ability of u-PAR 
to modulate cell morphology by binding to integrins and activating downstream cell 
signaling events causing morphological changes was recently investigated by two 
independent research groups (Madsen, Ferraris et al. 2007; Hillig, Engelholm et al. 
2008). There is a conflict regarding the necessity of Vtn for cytoskeleton rearrangement. 
Madsen et al., 2007, suggested that the u-PAR:Vtn interaction is necessary for changes in 
morphology, but the studies imply that a lateral interaction between u-PAR and integrins 
is unnecessary. Mutations in the RGD portion of Vtn were essential for morphologic 
effects, which were absent in the VtnRAD mutant.  However, the RGD integrin binding 
site is lateral to the SMB domain in Vtn and is separate from the u-PAR binding region 
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(Madsen, Ferraris et al. 2007).  Hillig et al., (2008) on the other hand, reported that 
although cytoskeletal re-arrangement and adhesion was pronounced when u-PAR was 
expressed on the cell surface, their Vtn defective u-PAR mutant, (u-PARW32A), was 
incapable of producing the same effect (Hillig, Engelholm et al. 2008). However, 
cytoskeletal rearrangement was found to not be fully dependent on Vtn-adhesion. They 
found that u-PARW32A generated morphological changes independent of Vtn binding in 
the presence of scu-PA. A secondary protein, such as integrin, may mediate the observed 
u-PAR-dependent morphological changes. scu-PA can restore cell adhesion and 
morphology, except when either residues W32 and R91 are mutated (Ploug 2003; Madsen 
and Sidenius 2008). Although both studies have conflicting conclusions, they identify u-
PAR as a mediator of morphologic changes and the importance of u-PAR for Vtn 
adhesion, a trait that resonates with our results. A dramatic difference was seen due to 
expression of u-PAR. Expression of active u-PAR in the form of cr-uPAR may present a 
new challenge to a cell, since it does not appear to require the presence of u-PA. 
Although our studies were preformed mainly in the absence of exogenous u-PA these 
studies strongly supports the hypothesis that cr-uPAR is in a state that resembles the 
active conformation which affects process elongation, similar to the effect of bound u-
PA.  Our studies show that wt u-PAR and cr-uPAR have similar Vtn adhesion, potentially 
due to excess receptor expression. Because of the small difference in Vtn adhesion and 
the small increase in initial internalization reported in the previous chapter, there may be 
a small population of u-PAR that interacts with LRP, not Vtn. In addition, the most 
probable binding site for Vtn and LRP is the opposite site of the u-PA cavity. Thus, the 
availability of the receptor is limited to which molecule it is interacting with.  
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Efforts to distinguish between intact u-PAR and cleaved u-PAR were performed by 
using either inactive u-PA or the ATF of u-PA that is devoid of its proteolytic domain.  
Binding of u-PA was found to be sufficient for a morphological effect, but cleaved u-
PAR generated a stronger effect. Studies performed with a synthetic peptide mimicking 
u-PA do not entirely recover the u-PAR mutant conformational change, suggesting that 
there is a minimal conformational change necessary to induce the same conformation as a 
u-PA bound u-PAR. Thus, we hypothesize that the activation of u-PAR can support cell 
signaling sufficient to induce morphology changes and cytoskeletal rearrangement.  We 
also suggest that there is a small population of receptors in a similar conformation that 
can promote the events in the absence of any external stimulus, since most of our studies 
are based on basal studies and do not include human u-PA. We speculate that the 
observed morphological and adhesion changes may be due to cell signaling which is 
unregulated by cr-uPAR.  
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5.4.  Figures and Tables 
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CHAPTER 6. CELLULAR RESPONSES CHANGE DRAMATICALLY WHEN 
CR-UPAR IS EXPRESSED.  
 
6.1. Introduction:  
The function of the u-PA/u-PAR system was originally thought to be limited to 
localizing the Pg activation cascade and promoting pericellular proteolysis. More recently 
expression of u-PAR has been attributed to cancer progression and metastasis in mice 
that is u-PA-independent (Jo, Takimoto et al. 2009). Additionally, in thyroid carcinoma 
an increasing degree of metastasis follows a parallel pattern of u-PAR cleavage 
resistance.   
Like many other GPI-anchored proteins, u-PAR can participate in cell signaling 
events which can affect multiple cellular events (Barker, Pallero et al. 2004). Although u-
PAR is not a transmembrane protein, it interacts with many transmembrane proteins, i.e. 
integrins, GPCR, FPRL1, and LRP. These interactions activate many cellular signaling 
pathways, which include ERK/MAPK, focal adhesion kinase (FAK), JAK/ STAT, Rac-1, 
Src, and tyrosine- and serine-protein kinases (D'Alessio and Blasi 2009). Not all 
functions affected by cell-signaling events are u-PA dependent.  Indeed, u-PAR 
expression can induce cellular adhesion that is mediated exclusively by Vtn, since over-
expression of u-PAR can make the Vtn effect u-PA-independent. In addition, u-PAR can 
interact with integrins to regulate their activation or deactivation.  Both of these effects 
are nullified when the D1 of u-PAR is removed.  In migrating cells, u-PAR has been 
detected at the leading edge, an area of lamellipodia formation.  Furthermore, cell 
migration via u-PAR is usually enhanced through conformational changes induced by u-
PA, which leads to exposure of the chemotactic epitope either by u-PAR activation or the 
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cleavage of D1.  The presence of u-PA also leads to increased cell proliferation via 
activation of the ERK/MAPK pathway.  To our knowledge ligand-induced activation is 
sufficient for these events to occur, but it still remains unclear whether conversion to the 
fully active cleaved form is necessary for the events to persist or if cleavage is just a key 
regulatory point that diverges from Vtn and integrin-induced events. 
Studies performed on u-PAR knockout mice indicated that homozygotes reached 
adulthood and reproduced normally (Bugge, Suh et al. 1995).  However, the lack of u-
PAR caused dramatic changes in several cell signaling pathways, which in turn affected 
cell proliferation, adhesion, migration, and differentiation.  When u-PA and u-PAR 
expression were knocked down via hairpin RNA (hpRNA), there was a decrease in 
phosphorylation of ERK1/2, JNK, p38, FAK and PI(3)K, all major players in 
proliferation and survival (Gondi, Kandhukuri et al. 2007). u-PAR and integrin α5β1 
activate ERK via EGRF, in a FAK-dependent manner, promoting cancer cell growth 
(Aguirre-Ghiso, Liu et al. 2001). Studies using a scid mouse model demonstrated that 
expression of u-PAR leads to metastasis that is independent of u-PA (Jo, Takimoto et al. 
2009).  
In this chapter, we show that the inability to cleave cr-uPAR results in the inability of 
u-PAR to regulate its multiple interactions, heightening most of the biological functions 
studied.  However, cr-uPAR did not diverge from the pathways normally used by wt u-
PAR.  We hypothesize that expression of cr-uPAR in a conformation similar to the u-PA 
bound u-PAR leads to changes in the phenotype of 293 cr-uPAR cells, which resemble 
the well defined characteristics of a cancer cell.  Thus, the modulation of u-PAR activity 
may play a role in both physiological and pathophysiological events. 
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6.2. Results: 
6.2.1. cr-uPAR expression accelerates cellular proliferation independent of u-
PA.  
Since u-PAR is over-expressed in tumor cells and can modulate tumor growth,  we 
speculated that u-PAR can regulate tumor proliferation and tumor progression.  Cells 
expressing u-PAR have cell morphological changes and enhanced Vtn adhesive 
properties (Chapter 5).  Also, after stable transfection 293 cr-uPAR cells appeared to 
reach confluency much faster than 293 non-transfected cells and 293 wt u-PAR cells.  
Thus, we determined whether the presence of cr-uPAR alters cell growth to the extent 
previously observed when u-PA stimulated u-PAR.  
Figure 6.2.1 shows that 293 wt u-PAR cells exhibited the same doubling time as non-
transfected, mock, or plasmid-only transfected 293 cells , ~39 h (Table VI).  In contrast, 
293 cr-uPAR cells showed a 1.5-fold faster doubling time at ~25 h.  This trend was 
independent of receptor expression level as shown via monitoring of different clones of 
wt u-PAR or cr-uPAR expressing cells (Table VI).  u-PAR induces cell proliferation in 
part by activating the ERK pathway, which can be interrupted by using the MEK 
inhibitor, PD98059.  Proliferation of 293 cells was nearly completely abolished by the 
addition of PD98059 (Fig. 6.2.2 A). On the other hand the presence of PD98059 only 
suppressed approximately 50% of cell growth of wt u-PAR or cr-uPAR expressing cells. 
Since over-expression of u-PAR can stimulate the JNK pathway as well, we similarly 
studied its contribution to u-PAR-dependent proliferation using the JNKII inhibitor, 
JNKi.  JNKi was able to significantly suppress the proliferation of non-transfected 293 
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cells.  The addition of JNKi modestly decreased the proliferation of wt u-PAR cells 
(18%), while strongly affecting cr-uPAR cells (52%).  Treating cells with PD98059 and 
JNKi jointly suppressed cell proliferation of 293 wt u-PAR and 293 cr-uPAR cells in a 
manner that resembled the additive effects of either treatment alone.  The presence of u-
PA induced the proliferation of cells expressing u-PAR (Fig. 6.2.2 B).  Addition of u-PA 
had no effect on 293 cells since they do not express u-PAR.  Addition of PD98059 or 
JNKi suppressed the proliferation of wt u-PAR cells in the presence of u-PA to nearly 
50%, when compared to its absence. Cell proliferation of 293 cr-uPAR cells in the 
presence of PD98059 or JNKi and u-PA had similar effects as in the presence of serum.  
These results suggest that unliganded wt u-PAR predominantly stimulates cellular 
proliferation via the ERK pathway, while binding to u-PA also activates the JNK 
pathway.  293 cr-uPAR cells utilize both ERK and JNK pathways to promote 
proliferation even in the absence of u-PA, indicating that the free mutant receptor is 
stimulating cell proliferation in a similar manner as u-PA-bound receptor 
 
6.2.2. The presence of cell-surface cr-uPAR enhances basal activation of ERK 
similar to active wt u-PAR.   
u-PAR expression on 293 cells upregulates basal ERK activation.  Serum stimulation 
of 293 cells enhances ERK activation (Fig. 6.2.3 A and B). 293 non-transfected cells had 
undetectable ERK phosphorylation with an 8-fold increase when serum stimulated. The 
addition of PD98059 to serum-stimulated 293 cells reduced ERK phosphorylation to 
basal levels. Unstimulated 293 wt u-PAR cells had a 4-fold increase in basal ERK 
phosphorylation while the addition of serum caused a 2.8-fold increase in ERK 
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phosphorylation over baseline. Basal levels of ERK phosphorylation in 293 cr-uPAR 
cells was 4-fold higher than the basal levels observed in 293 wt u-PAR cells, which 
corresponded to the changes seen in cell proliferation. The binding of the ATF to cells 
expressing uPAR led to a 5.5-fold increase in ERK phosphorylation of 293 cr-uPAR 
cells, compared to 293 wt u-PAR basal ERK phosphorylation (Fig. 6.2.3 C and D). The 
addition of PD98059 in the presence or absence of JNKi led to significant, but 
incomplete, attenuation of ERK activation only in 293 cr-uPAR cells. Exposure of cells 
with the JNKi and PD98059 did not significantly reduced ERK signaling.   
  
6.2.3. Both wt u-PAR and cr-uPAR cell variants use additional signaling 
pathways. 
In cancer, over-expression of uPAR induces JNK activation (Aguirre-Ghiso; 1999), 
raising the question whether the altered biological changes observed in 293 cr-uPAR cells 
are due to the induction of an alternate signaling pathway. Thus, wt u-PAR and cr-uPAR 
cells were tested for changes in JNK phosphorylation (Fig. 6.2.3 E and F). There was an 
increase in basal JNK phosphorylation in cr-uPAR expressing cells that was not detected 
in 293 wt u-PAR cells.  However, 293 wt u-PAR cells stimulated with serum had a slight 
increase in JNK phosphorylation. These results are in agreement with the observed 
changes in cr-uPAR dependent proliferation. In 293 wt u-PAR cells, the addition of ATF 
had no effect on JNK phosphorylation. Interestingly, when cells were exposed to the 
JNKi in the presence of uPA and/or PD98059, JNK activation was not completely 
inhibited, suggesting that there may be cross-talk between pathways. These studies also 
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suggest that cr-uPAR can use a secondary pathway to enhance downstream cell signaling 
events and further promote proliferation. 
 
6.2.4. Decreased apoptosis contributes to the enhanced cell number seen in 293 
cr-uPAR cell cultures. 
To determine if the enhanced proliferation observed in 293 cr-uPAR cells was based 
on an increased proliferation rate or a decrease in apoptosis, we quantified the number of 
apoptotic non-transfected, wt u-PAR and cr-uPAR cells after normal growth.  Cells were 
Hoechst stained and visually scored for chromatin condensation as a sign of apoptotic 
change (Fig. 6.2.4 A-D). In 293 cell cultures and cultures of cells expressing wt u-PAR 
the Hoechst intensity per cell was similar, and thus the number of cells undergoing 
apoptosis is similar (Fig. 6.2.4 B). In contrast, 293 cr-uPAR cells had a decrease in 
Hoechst intensity, which suggests that the mutant receptor protects against induced 
apoptosis (Fig. 6.2.4 C). To determine if this effect was reproducible when apoptosis was 
induced, we stained the cells with PE-Annexin V in the presence or absence of TNF-α  
and CHX (Fig. 6.2.4 E). We observed no difference in apoptosis under normal 
conditions.  However, in the presence of TNF-α there was an increase in apoptosis for the 
non-transfected cells. There was a moderate protection when wt u-PAR was expressed. 
Protection against apoptosis was more pronounced when cr-uPAR was expressed. Thus 
these studies suggest the enhanced proliferation of cr-uPAR cells results from a 
combination of increased cellular division and decreased cell death. This led us to study 
overall cell death induced by serum starvation, with CO2 depravation, or serum starvation 
and the addition of TNF-α (Fig. 6.2.5 A). We observed that 293 cr-uPAR cells were less 
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affected than 293 non-transfected cells and 293 wt u-PAR cells.  A 30% rate of cell death 
compared was seen for cr-uPAR cells undergoing serum starvation relative to 60 and 
70% cell death for 293 non-transfected and wt u-PAR cells, respectively. Thus, cr-uPAR 
expression can enhance cell survival. 
An additional study was performed to determine whether increased apoptosis 
contributes to the increase in cell numbers seen in cr-uPAR cell cultures. The first study 
sought to identify changes in proteins associated with apoptosis under basal conditions. 
Basal levels of activated caspase 3/7 were indistinguishable between the three cell lines 
(Fig. 6.2.5 B).  However, 293 cells treated with TNF-α had 3-fold higher caspase activity, 
than wt u-PAR or cr-uPAR expressing cells.  Interestingly, there was a pronounced 
decrease in caspase activity in cr-uPAR cells relative to wt u-PAR cells.  These results 
suggest that the effects observed in proliferation are not an immediate result of resistance 
to apoptosis, since there is no basal difference in cell death between the cells, a trait also 
observed in the highly metastatic ARO cells (Int. J. Cancer 81:956-962, 1999). The 
observed increase in apoptosis in the presence of u-PA in cr-uPAR cells and the lack of 
significant difference in the presence of PD98059 suggests that cr-uPAR may use other 
pathways to control these events. 
  
6.2.5. Expression of cr-uPAR promotes migration paralleling the effects of 
activated  wt u-PAR. 
We hypothesized that cr-uPAR induces enhanced migration similar to the u-PA-
bound active form of u-PAR.  Using serum as a stimulus, we observed that non-
transfected 293 cells were unaffected by the presence of either Vtn based matrix (Fig. 
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6.2.6) or serum based matrix (Fig. 6.2.7).  293 cells expressing wt u-PAR or cr-uPAR had 
slightly reduced migration in the absence of stimulus compared to untransfected cells, 
which might be  due to increased cellular adhesion secondary to u-PAR expression (Wei, 
Waltz et al. 1994).  On exposure to serum, cells expressing wt u-PAR had an approximate 
200% increase in migration compared to normal controls, while cells expressing cr-uPAR 
had an approximate 300% increase in migration compared to controls.  Stimulation with 
tcu-PA increases migration of cells expressing wt u-PAR.  Thus, we asked whether wt u-
PAR cells that had been stimulated with a low dose of tcu-PA increased migration to the 
levels seen for cr-uPAR cells (Fig. 6.2.6).  Stimulation of wt u-PAR with tcu-PA caused 
an approximate 400% increase in migration.  However, when cr-uPAR cells were 
stimulated, we observed no significant change in migration when compared to the basal 
migration. This was not due to random chemotaxis as cell expressing either u-PAR 
variants had little directed migration in the absence of serum (Figure  6.2.8).  
 
6.2.6. Migration via the GPCR pathway is unaffected by the presence of cr-
uPAR. 
Expression of unoccupied uPAR leads to limited cell migration, since the cryptic 
chemotactic epitope needed for migration is unavailable to interact with pro-migratory 
receptors, most notably GPCRs (Mazzieri, D'Alessio et al. 2006). We previously found 
that cells expressing cr-uPAR exhibited an enhanced basal tendency to migrate as 
compared to wt u-PAR cells.  u-PA further stimulated the migration of wt u-PAR cells 
but not of cr-uPAR cells, suggesting that cr-uPAR expression promoted cell migration in 
a ligand-independent manner.  To determine whether cr-uPAR also utilized GPCR 
signaling to induce cell migration, we monitored the effect of the GPCR pathway 
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inhibitor, pertussis toxin (PTX) on the migration of wt u-PAR and cr-uPAR cells (Fig. 
6.2.9).  In the absence of PTX, 10% FCS as a general chemoattractant induced a two-fold 
increase in migration in wt u-PAR cells over their basal migration rate without serum.  As 
previously reported, the FCS-stimulated migration rate of cr-uPAR cells is approximately 
another two-fold higher than that of wt u-PAR cells (Nieves and Manchanda 2010).  
Binding of u-PA induces a similar two-fold enhancement of wt u-PAR cell migration.  
However, u-PA has no additional stimulatory effect on cr-uPAR cell migration.  Pre-
incubation of either wt u-PAR or cr-uPAR cells with PTX abolishes serum-dependent 
migration regardless of the presence of the u-PA stimulant.  These results suggest that 
293 cr-uPAR cells use the GPCR pathway to induce migration, similar to 293 wt u-PAR 
cells. Furthermore they indicate that while unliganded cr-uPAR promotes cellular 
migration similar to ligand-activated wt u-PAR, both receptors utilize GPCR pathways to 
regulate the process. 
 
6.3. Discussion: 
In thyroid cancer cells resistance to u-PAR cleavage correlates with cancer 
malignancy. ARO, anaplastic thyroid cancer cells, also have abundant levels of u-PAR 
but are resistant to cleavage by tcu-PA. WRO, a follicular thyroid carcinoma, have less 
cleavage resistance than their ARO counterpart and decreased malignancy (Ragno, 
Montuori et al. 1998). 
Expression levels of both u-PA and u-PAR correlates to patient outcome, metastatic 
potential (in vitro), and tumor progression (Pyke, Kristensen et al. 1991; Plesner, 
Ralfkiaer et al. 1994; Carriero, Del Vecchio et al. 1997). The role of u-PAR in 
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malignancy is accentuated by the ability of PAI-1 to inhibit migration of tumor cells, 
implying u-PAR is a potential regulatory target of cancer malignancy.  Indeed, u-PAR 
can induce tumor progression and metastasis in the absence of u-PA (Jo, Takimoto et al. 
2009). In many cancers, the MAPK/ERK pathways are frequently hyper-expressed and 
over-active (Sivaraman, Wang et al. 1997). The increase in ERK phosphorylation seen in 
cr-uPAR cells is most likely mediated by the presence of an active receptor, which in turn 
can activate downstream genes responsible for driving the cells into S-phase.  Our studies 
here are focused on determining the differences between the basal effects from the u-
PAR variants rather than pinpointing which pathway is responsible for these cellular 
changes. Mazzieri et al., reported that a highly mutated receptor with a total of 5 residues 
altered in the linker region alone produced a u-PAR that is resistant to cleavage by tcu-
PA, Pn, chymotrypsin and MMPs.  They observed a change in protein interaction which 
lead the receptor to interact prominently with EGFR and integrin α5β1 but is unable to 
interact with FPRL-1.  However, in our system we show that cr-uPAR can interact with 
Vn, unlike the hcr-uPAR mutant. Madsen et al, showed that switching key residues in u-
PAR can lead to disruption of Vtn interaction, residues W32 and R91, and decrease both 
adhesion and changes in cell morphology.  Although, our mutant has two sites mutated in 
the linker region between D1 and D2, we show that most of the normal interactions are 
maintained, since there is no loss of wild-type features.  
The lack of regulation of u-PAR activation, cleavage and protein interactions 
promotes enhanced cellular functions that resemble characteristics of a cancer cell. The 
ability of cr-uPAR expressing cells to proliferate faster in the absence of u-PA is only one 
example of this dysregulation.  Indeed, cr-uPAR cells promote cell proliferation in the 
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presence of PD98059, a MEK inhibitor. Yet the addition of a JNK inhibitor in tandem 
with PD98059 is capable of preventing cell growth. This suggests that more than one 
pathway is activated by the presence of cr-uPAR. This effect is reproduced in cell 
migration, a mechanism that also utilizes cell signaling events to mediate the function 
(Fig. 6.2.6).  We observed that in the absence of u-PA there is significant stimulation of 
directed migration. However, cr-uPAR uses the same pathway as wt u-PAR, since the 
GPCR uncoupler, PTX, prevents any cell migration (Fig. 6.2.14). Unlike the observations 
made with hcr-uPAR, our cr-uPAR did not diverge from utilizing wt u-PAR pathways.  
These results also suggest that u-PAR adapts to its environment, adding to the 
complicated knowledge we have of this system. The cr-uPAR receptor seems in a 
structural change that resembles that of the active receptor.  This change leads to a hyper-
active state, a lack of regulation by u-PA and the system, not to mention instead of 
separating each individual component has brought together both the ability to 
constitutively maintain functions associated with Vtn and integrins, and those functions 
associated with the cleaved form of u-PAR. cr-uPAR behavior like the active receptor, 
most probably having the chemotactic epitope exposed, induces the capabilities which to 
date have only been observed to be u-PA dependent.  
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6.4. Figures and Tables:  
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CHAPTER 7: SUMMARY AND NEW DIRECTIONS 
 
Upregulated expression of u-PAR on cancer cells as well as associated stromal and 
inflammatory cells occurs in a wide array of cancers and can correlate with increased 
metastasis, resistance to chemotherapy, and overall poor prognosis depending on the type 
of malignancy (Andreasen, Kjoller et al. 1997; Ge and Elghetany 2003).  Elevated levels 
of cleaved u-PAR is an independent prognostic marker for several cancers as well 
(Pedersen, Schmitt et al. 1993; Sidenius, Sier et al. 2000; Garcia-Monco, Coleman et al. 
2002).  However, since cleaved u-PAR can promote cellular migration in vitro, it is 
unclear whether the presence of elevated serum soluble cleaved receptor in certain cancer 
patients merely reflects increased levels of u-PA activity or reflects a cleavage-mediated 
receptor activation mechanism. Confounding the interpretation of the clinicopathological 
data is that in certain highly invasive cancers, such as anaplastic thyroid carcinoma, 
overglycosylation of u-PAR allows u-PA-binding but hinders u-PA-dependent receptor 
cleavage (Montuori, Rossi et al. 1999).  Nevertheless, because of its wide prognostic 
value, u-PAR has emerged as an attractive target for the development of small molecule 
antagonists. This emerging area of research highlights the need for a better understanding 
of the cellular biology of u-PAR and how its functions might be modulated by such small 
molecules. 
Here we intended to discern the differences between the generation of cleaved u-PAR 
and the u-PAR activation post-exposure to u-PA. The studies shown here were performed 
using a mutant form of u-PAR, cr-uPAR, resistant to u-PA cleavage that resulted in a 
novel internalization profile, heightened cell proliferation, heightened cell migration, 
hyper-activated ERK and increased processes elongation, which were u-PA independent 
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at basal states. Cr-uPAR remained intact in the presence of vast stoichiometric excess of 
u-PA, suggesting that the ligand-induced receptor cleavage by non-specific proteases is 
unlikely. Overall, these studies showed an indiscriminant use of both a proteolytic and a 
non-proteolytic role by the generation of a cr-uPAR (Nieves and Manchanda 2010). 
These observations in combination with cellular and biological studies performed by 
other researchers suggest a series of conformational changes occur in different forms of 
u-PAR, i.e. unliganded or u-PA-bound.  In addition to cellular studies, reported crystal 
structures in the presence of several binding molecules showed different conformational 
changes, reflective of a highly mobile linker region and domains. Our study gives novel 
insights into the events that are affected by the conformational state of the receptor.  It 
would be intriguing to crystallize cr-uPAR to determine similarities with the u-PA bound 
u-PAR, since cr-uPAR activity resembles that of ligand-bound wt u-PAR. We observed 
cr-uPAR-expressing cells, in the absence u-PA, perform the functions of cellular 
migration and cellular proliferation to an extent similar to u-PA-treated cells expressing 
wt u-PAR. 
There are two proposed models for u-PAR. One suggests binding of u-PA leads to a 
conformational change which exposes the chemotactic epitope, activating the receptor 
and initiating the correspondent cellular events. The second model suggests that binding 
of u-PA promotes cleavage and thus exposure of the linker region, leading to regulation 
of u-PAR’s functions with the generation of the permanently active form of u-PAR.  We 
challenged both models by preventing u-PAR cleavage and promoting the dysregulation 
of several key activities. 
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Our data are congruent with a functional model of u-PAR in which the receptor can 
be induced to adopt a range of activities based on the presence of ligand and the 
availability of co-receptors as defined by their membrane distribution.  This functional 
model complements a recently described structural model in which unliganded u-PAR is 
proposed to be in dynamic equilibrium among several conformations as defined by the 
receptor's interdomain relationships.  Some of these conformations have limited activity, 
such as moderate affinity for Vtn, while others are wholly inactive, and can be stabilized 
via small molecule u-PAR antagonists (Huai, Mazar et al. 2006; Madsen, Ferraris et al. 
2007; De Souza, Matthews et al. 2011).  In both models, fully active u-PAR is induced by 
u-PA-binding.  Within this structural model, it may be possible for different protein-
protein binding sites to exhibit dyssynchronous competencies in unliganded u-PAR, and 
it is only when u-PA is present to lock the receptor into a globally active conformation 
such that u-PAR's affinities for other co-receptors are fully revealed (Huai, Mazar et al. 
2006; Xu, Gardsvoll et al. 2012).  This dyssynchronous binding potential of unliganded 
u-PAR conformers could contribute to the differing degrees of pro-migratory versus pro-
proliferative effects of cr-uPAR expression in the presence and absence of u-PA. 
Our original goal was to dissect those functions that were exclusive to the intact 
receptor. We were surprised to discover that cr-uPAR retained all tested functions. These 
studies suggest a need for u-PAR cleavage to hinder the multiple events that are induced 
from over-stimulating the cell and dysregulating its normal functions.   Removing the 
proteolytic sites of u-PAR caused an unexpected gain of cancer cell-like characteristics.  
Whether cr-uPAR leads to a stronger metastatic profile in a scid mouse model implanted 
with cells expressing human u-PAR in the presence or absence of human u-PA is yet to 
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be determined.  In addition, at the geriatric state, u-PAR knockout mice have differences 
in leukocyte infiltration (Gueler, Rong et al. 2008).  The fact that different mouse models 
have been used makes understanding the in vivo functions of u-PAR more difficult; 
however, it is feasible to use cr-uPAR as a tool to study regulation differences.  The 
development of a knock-in human cr-uPAR mouse model can be generated to study the 
effects on auto-regulation of u-PAR functions.  In addition, our molecule can potentially 
be used to isolate the molecular mechanisms underlying u-PAR’s role in human 
malignancies. A confounding finding in our studies is the gain of interaction with LRP. 
Interestingly, the original function of u-PAR, the initiation of the plasminogen system, at 
first glance still occurs with cr-uPAR.  However, a closer look at both receptor saturation 
and reversible inhibition demonstrated a crucial distinction between the two u-PAR 
variants used in this study.  Again, these observations suggest that the lack of a regulation 
by proteolysis causes dysregulation of cr-uPAR activity. Additionally, cr-uPAR’s ability 
to stimulate multiple pathways similar to both the intact and the cleaved form of u-PAR 
can be used to further isolate differences in the signaling pathways of the u-PA-bound u-
PAR and the cleaved u-PAR, if they exist.  
The regulation of u-PAR activity remains complex.  While receptor cleavage does not 
appear to be a primary mechanism for initiating any of these functions, it is unknown 
whether cleavage is a physiologic means of receptor downregulation or perhaps a switch 
from matrix adhesion to stimulating migration.  Moreover, ancillary observations on the 
cellular biology of cr-uPAR have yielded new testable hypotheses on the regulation of 
receptor activity by membrane trafficking.  While dissection of these regulatory pathways 
is crucial to the development of anti-u-PAR therapeutic agents, the current data also 
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caution that u-PAR has the potential to be fixed in a uPA-independent, partially active 
state. 
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